

# Bradley T Hyman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6204625/publications.pdf>

Version: 2024-02-01

598  
papers

121,978  
citations

154

156  
h-index

154

325  
g-index

642  
all docs

642  
docs citations

642  
times ranked

81850  
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors of the importance of everyday preferences for older adults with cognitive impairment. <i>International Psychogeriatrics</i> , 2022, 34, 287-294.	1.0	6
2	Systematic review of human post-mortem immunohistochemical studies and bioinformatics analyses unveil the complexity of astrocyte reaction in Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	3.2	40
3	Current directions in tau research: Highlights from Tau 2020. <i>Alzheimer's and Dementia</i> , 2022, 18, 988-1007.	0.8	42
4	Longitudinal Changes in Neuropsychiatric Symptoms: Impact of Discrepancy in Everyday Preferences Between Persons With Cognitive Impairment and Their Care Partners. <i>American Journal of Geriatric Psychiatry</i> , 2022, 30, 619-623.	1.2	4
5	Pathogenic tau accelerates aging-associated activation of transposable elements in the mouse central nervous system. <i>Progress in Neurobiology</i> , 2022, 208, 102181.	5.7	32
6	Genome-wide association study and functional validation implicates JADE1 in tauopathy. <i>Acta Neuropathologica</i> , 2022, 143, 33-53.	7.7	19
7	Novel genetic variants in <i>MAPT</i> and alterations in tau phosphorylation in amyotrophic lateral sclerosis post-mortem motor cortex and cerebrospinal fluid. <i>Brain Pathology</i> , 2022, 32, e13035.	4.1	15
8	Targeting Tau Mitigates Mitochondrial Fragmentation and Oxidative Stress in Amyotrophic Lateral Sclerosis. <i>Molecular Neurobiology</i> , 2022, 59, 683-702.	4.0	18
9	Cyclic multiplex fluorescent immunohistochemistry and machine learning reveal distinct states of astrocytes and microglia in normal aging and Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2022, 19, 30.	7.2	15
10	In situ structural biology of pathological protein deposits in Alzheimer's disease. <i>Biophysical Journal</i> , 2022, 121, 153a.	0.5	0
11	A Nuclear Magnetic Resonance Spectroscopy Method in Characterization of Blood Metabolomics for Alzheimer's Disease. <i>Metabolites</i> , 2022, 12, 181.	2.9	5
12	Tau propagation is dependent on the genetic background of mouse strains. <i>Brain Communications</i> , 2022, 4, fcac048.	3.3	8
13	APOE4 derived from astrocytes leads to blood-brain barrier impairment. <i>Brain</i> , 2022, 145, 3582-3593.	7.6	52
14	Somatic genomic changes in single Alzheimer's disease neurons. <i>Nature</i> , 2022, 604, 714-722.	27.8	92
15	Mapping the Spatial Distribution of Fibrillar Polymorphs in Human Brain Tissue. <i>Frontiers in Neuroscience</i> , 2022, 16, .	2.8	4
16	Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment. <i>Brain Communications</i> , 2022, 4, .	3.3	11
17	APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. <i>Lancet Neurology</i> , The, 2021, 20, 68-80.	10.2	399
18	Systematic review and meta-analysis of human transcriptomics reveals neuroinflammation, deficient energy metabolism, and proteostasis failure across neurodegeneration. <i>Neurobiology of Disease</i> , 2021, 149, 105225.	4.4	54

#	ARTICLE	IF	CITATIONS
19	A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer's disease. <i>Acta Neuropathologica</i> , 2021, 141, 217-233.	7.7	33
20	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. <i>JAMA Neurology</i> , 2021, 78, 102.	9.0	144
21	Conformational fingerprinting of tau variants and strains by Raman spectroscopy. <i>RSC Advances</i> , 2021, 11, 8899-8915.	3.6	15
22	Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model. <i>Annals of Neurology</i> , 2021, 89, 952-966.	5.3	36
23	Machine learning identifies candidates for drug repurposing in Alzheimer's disease. <i>Nature Communications</i> , 2021, 12, 1033.	12.8	124
24	In Situ Studies of Fibrillar Polymorphs in Alzheimer's Disease. <i>Biophysical Journal</i> , 2021, 120, 351a-352a.	0.5	0
25	Association of <i>APOE</i> Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease. <i>Neurology</i> , 2021, 96, e2414-e2428.	1.1	34
26	Quantitative Methods for the Detection of Tau Seeding Activity in Human Biofluids. <i>Frontiers in Neuroscience</i> , 2021, 15, 654176.	2.8	4
27	Persistent repression of tau in the brain using engineered zinc finger protein transcription factors. <i>Science Advances</i> , 2021, 7, .	10.3	31
28	Differential gene expression data from the human central nervous system across Alzheimer's disease, Lewy body diseases, and the amyotrophic lateral sclerosis and frontotemporal dementia spectrum. <i>Data in Brief</i> , 2021, 35, 106863.	1.0	6
29	Acetylated tau inhibits chaperone-mediated autophagy and promotes tau pathology propagation in mice. <i>Nature Communications</i> , 2021, 12, 2238.	12.8	101
30	Continuous Monitoring of Tau-Induced Neurotoxicity in Patient-Derived iPSC-Neurons. <i>Journal of Neuroscience</i> , 2021, 41, 4335-4348.	3.6	10
31	Kinetics of tau aggregation reveals patient-specific tau characteristics among Alzheimer's cases. <i>Brain Communications</i> , 2021, 3, fcab096.	3.3	7
32	Visit-to-Visit Blood Pressure Variability, Neuropathology, and Cognitive Decline. <i>Neurology</i> , 2021, 96, e2812-e2823.	1.1	33
33	Alzheimer disease. <i>Nature Reviews Disease Primers</i> , 2021, 7, 33.	30.5	784
34	Systematic in silico analysis of clinically tested drugs for reducing amyloid-beta plaque accumulation in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1487-1498.	0.8	22
35	Cytoplasmic Mislocalization of RNA Polymerase II Subunit RPB1 in Alzheimer Disease Is Linked to Pathologic Tau. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 530-540.	1.7	6
36	An integrated genomic approach to dissect the genetic landscape regulating the cell-to-cell transfer of tau-synuclein. <i>Cell Reports</i> , 2021, 35, 109189.	6.4	8

#	ARTICLE	IF	CITATIONS
37	Genome-encoded cytoplasmic double-stranded RNAs, found in <i>C9ORF72</i> ALS-FTD brain, propagate neuronal loss. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	27
38	Impairment of visual cortical plasticity by amyloid-beta species. <i>Neurobiology of Disease</i> , 2021, 154, 105344.	4.4	8
39	Longitudinal differences in everyday preferences: Comparisons between people with cognitive impairment and their care partners. <i>International Journal of Geriatric Psychiatry</i> , 2021, . .	2.7	3
40	Impact of Sterilization Methods on the Seeding Ability of Human Tau Proteopathic Seeds. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 912-921.	1.7	0
41	Computational Interspecies Translation Between Alzheimer's Disease Mouse Models and Human Subjects Identifies Innate Immune Complement, TYROBP, and TAM Receptor Agonist Signatures, Distinct From Influences of Aging. <i>Frontiers in Neuroscience</i> , 2021, 15, 727784.	2.8	4
42	Synaptic proteins associated with cognitive performance and neuropathology in older humans revealed by multiplexed fractionated proteomics. <i>Neurobiology of Aging</i> , 2021, 105, 99-114.	3.1	32
43	Regulation of tau internalization, degradation, and seeding by LRP1 reveals multiple pathways for tau catabolism. <i>Journal of Biological Chemistry</i> , 2021, 296, 100715.	3.4	52
44	Effect of APOE alleles on the glial transcriptome in normal aging and Alzheimer's disease. <i>Nature Aging</i> , 2021, 1, 919-931.	11.6	13
45	In vivo rate-determining steps of tau seed accumulation in Alzheimer's disease. <i>Science Advances</i> , 2021, 7, eabh1448.	10.3	70
46	Heterogeneity of Tau Deposition and Microvascular Involvement in MCI and AD. <i>Current Alzheimer Research</i> , 2021, 18, 711-720.	1.4	6
47	Characterization of glial responses in Alzheimer's disease with cyclic multiplex fluorescent immunohistochemistry and machine learning. <i>Alzheimer's and Dementia</i> , 2021, 17, e050902.	0.8	0
48	Active deep learning to detect cognitive concerns in electronic health records. <i>Alzheimer's and Dementia</i> , 2021, 17, e055362.	0.8	1
49	Rate-limiting processes of tau aggregate accumulation in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
50	Optimization of biosensor cell lines for the detection of tau seeding competency in human CSF. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
51	Heterogeneity of tau deposition and microvascular involvement in MCI and AD.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e054282.	0.8	0
52	Characterization of the 18 kDa translocator protein (TSPO) expression in <i>post-mortem</i> normal and Alzheimer's disease brains. <i>Brain Pathology</i> , 2020, 30, 151-164.	4.1	81
53	$\Delta$ -Synuclein strains target distinct brain regions and cell types. <i>Nature Neuroscience</i> , 2020, 23, 21-31.	14.8	195
54	Characterizing Clinical and Neuropathological Traits of APOE Haplotypes in African Americans and Europeans. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 467-477.	2.6	5

#	ARTICLE	IF	CITATIONS
55	Synaptic and metabolic gene expression alterations in neurons that are recipients of proteopathic tau seeds. <i>Acta Neuropathologica Communications</i> , 2020, 8, 168.	5.2	2
56	Risk of Transmissibility From Neurodegenerative Disease-Associated Proteins: Experimental Knowns and Unknowns. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 1141-1146.	1.7	24
57	Cerebrovascular Senescence Is Associated With Tau Pathology in Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 575953.	2.4	45
58	Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer's Disease. <i>Cell</i> , 2020, 183, 1699-1713.e13.	28.9	354
59	Synergy between amyloid- $\beta$ and tau in Alzheimer's disease. <i>Nature Neuroscience</i> , 2020, 23, 1183-1193.	14.8	579
60	Meta-analysis of mouse transcriptomic studies supports a context-dependent astrocyte reaction in acute CNS injury versus neurodegeneration. <i>Journal of Neuroinflammation</i> , 2020, 17, 227.	7.2	56
61	Tau reduction in aged mice does not impact Microangiopathy. <i>Acta Neuropathologica Communications</i> , 2020, 8, 137.	5.2	7
62	Meta-analysis of mouse transcriptomic studies supports a context-dependent astrocyte reaction in acute CNS injury versus neurodegeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, e040699.	0.8	0
63	Brain transcriptomes and plasma proteins reveal upregulation of a proinflammatory signature in APOE e4 carriers. <i>Alzheimer's and Dementia</i> , 2020, 16, e041316.	0.8	0
64	LRP1 mediates tau endocytosis in a process that is modulated by apolipoprotein E. <i>Alzheimer's and Dementia</i> , 2020, 16, e045959.	0.8	2
65	Plasma biomarkers of neuroinflammation and vascular injury predict cognitive decline in patients with mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, e046134.	0.8	2
66	The Alzheimer Disease-Causing Presenilin-1 L435F Mutation Causes Increased Production of Soluble A $\beta$ 43 Species in Patient-Derived iPSC-Neurons, Closely Mimicking Matched Patient Brain Tissue. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 592-604.	1.7	10
67	Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease. <i>Nature Medicine</i> , 2020, 26, 1256-1263.	30.7	262
68	$\beta$ -Glucocerebrosidase activity in GBA-linked Parkinson disease. <i>Neurology</i> , 2020, 95, e685-e696.	1.1	27
69	LRP1 is a master regulator of tau uptake and spread. <i>Nature</i> , 2020, 580, 381-385.	27.8	326
70	Differences in Assessment of Everyday Preferences Between People With Cognitive Impairment and Their Care Partners: The Role of Neuropsychiatric Symptoms. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 1070-1078.	1.2	11
71	Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study. <i>Nature Communications</i> , 2020, 11, 667.	12.8	246
72	Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson's Disease in the Harvard Biomarkers Study. <i>Journal of Parkinson's Disease</i> , 2020, 10, 505-510.	2.8	27

#	ARTICLE	IF	CITATIONS
73	PTEN activation contributes to neuronal and synaptic engulfment by microglia in tauopathy. <i>Acta Neuropathologica</i> , 2020, 140, 7-24.	7.7	24
74	Analysis of $\beta$ -synuclein species enriched from cerebral cortex of humans with sporadic dementia with Lewy bodies. <i>Brain Communications</i> , 2020, 2, fcaa010.	3.3	21
75	Tau propagation is dependent on the genetic background in multiple mouse strains. <i>Alzheimer's and Dementia</i> , 2020, 16, e043059.	0.8	0
76	Experimental evidence for the age dependence of tau protein spread in the brain. <i>Science Advances</i> , 2019, 5, eaaw6404.	10.3	103
77	Polygenic hazard score, amyloid deposition and Alzheimer's neurodegeneration. <i>Brain</i> , 2019, 142, 460-470.	7.6	63
78	The Major Risk Factors for Alzheimer's Disease: Age, Sex, and Genes Modulate the Microglia Response to $A\beta$ Plaques. <i>Cell Reports</i> , 2019, 27, 1293-1306.e6.	6.4	527
79	Novel methods for integration and visualization of genomics and genetics data in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 788-798.	0.8	18
80	Effects of Species-Specific Genetics on Alzheimer's Mouse Models. <i>Neuron</i> , 2019, 101, 351-352.	8.1	9
81	The NIH BRAIN Initiative: Integrating Neuroethics and Neuroscience. <i>Neuron</i> , 2019, 101, 394-398.	8.1	30
82	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates $A\beta$ , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	21.4	1,962
83	Tau impairs neural circuits, dominating amyloid- $\beta$ effects, in Alzheimer models in vivo. <i>Nature Neuroscience</i> , 2019, 22, 57-64.	14.8	278
84	Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer's disease. <i>Acta Neuropathologica</i> , 2019, 137, 209-226.	7.7	100
85	Beyond the neuron—cellular interactions early in Alzheimer disease pathogenesis. <i>Nature Reviews Neuroscience</i> , 2019, 20, 94-108.	10.2	237
86	Tau Prion-Like Propagation: State of the Art and Current Challenges. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1184, 305-325.	1.6	47
87	Cholinergic modulation of hippocampal calcium activity across the sleep-wake cycle. <i>ELife</i> , 2019, 8, .	6.0	28
88	Tau protein liquid—liquid phase separation can initiate tau aggregation. <i>EMBO Journal</i> , 2018, 37, .	7.8	696
89	Reversible Cation-Selective Attachment and Self-Assembly of Human Tau on Supported Brain Lipid Membranes. <i>Nano Letters</i> , 2018, 18, 3271-3281.	9.1	31
90	Mutant torsinA in the heterozygous DYT1 state compromises HSV propagation in infected neurons and fibroblasts. <i>Scientific Reports</i> , 2018, 8, 2324.	3.3	7

#	ARTICLE	IF	CITATIONS
91	Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1289-E1298.	7.1	224
92	Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 463-472.	1.5	41
93	Tau reduction in the presence of amyloid- $\beta^2$ prevents tau pathology and neuronal death in vivo. Brain, 2018, 141, 2194-2212.	7.6	84
94	CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer's Disease. Molecular Therapy - Nucleic Acids, 2018, 11, 429-440.	5.1	116
95	Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition. Acta Neuropathologica, 2018, 135, 85-93.	7.7	80
96	Partial reduction of microglia does not affect tau pathology in aged mice. Journal of Neuroinflammation, 2018, 15, 311.	7.2	52
97	Neuroethics Guiding Principles for the NIH BRAIN Initiative. Journal of Neuroscience, 2018, 38, 10586-10588.	3.6	61
98	Different tau species lead to heterogeneous tau pathology propagation and misfolding. Acta Neuropathologica Communications, 2018, 6, 132.	5.2	72
99	Secretion and Uptake of $\beta$ -Synuclein Via Extracellular Vesicles in Cultured Cells. Cellular and Molecular Neurobiology, 2018, 38, 1539-1550.	3.3	79
100	Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer's Disease. Neuron, 2018, 99, 925-940.e7.	8.1	302
101	The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer's disease. Journal of Neuroinflammation, 2018, 15, 269.	7.2	180
102	Virus vector-mediated genetic modification of brain tumor stromal cells after intravenous delivery. Journal of Neuro-Oncology, 2018, 139, 293-305.	2.9	24
103	A flow cytometry-based in vitro assay reveals that formation of apolipoprotein E (ApoE) amyloid beta complexes depends on ApoE isoform and cell type. Journal of Biological Chemistry, 2018, 293, 13247-13256.	3.4	11
104	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	12.6	1,085
105	Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain. Frontiers in Neuroscience, 2018, 12, 267.	2.8	198
106	$\beta^2$ -Amyloid Induces Pathology-Related Patterns of Tau Hyperphosphorylation at Synaptic Terminals. Journal of Neuropathology and Experimental Neurology, 2018, 77, 814-826.	1.7	46
107	Neuronal calcineurin transcriptional targets parallel changes observed in Alzheimer disease brain. Journal of Neurochemistry, 2018, 147, 24-39.	3.9	14
108	Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. Journal of Clinical Investigation, 2018, 128, 2144-2155.	8.2	105

#	ARTICLE	IF	CITATIONS
109	Dynamic presenilin 1 and synaptotagmin 1 interaction modulates exocytosis and amyloid $\beta$ production. <i>Molecular Neurodegeneration</i> , 2017, 12, 15.	10.8	26
110	Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. <i>Acta Neuropathologica</i> , 2017, 133, 825-837.	7.7	90
111	Association of In Vivo [ <sup>18</sup> F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease. <i>JAMA Neurology</i> , 2017, 74, 427.	9.0	236
112	Spread of tau down neural circuits precedes synapse and neuronal loss in the rTgTauEC mouse model of early Alzheimer's disease. <i>Synapse</i> , 2017, 71, e21965.	1.2	53
113	Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro. <i>American Journal of Pathology</i> , 2017, 187, 1399-1412.	3.8	92
114	Enhanced Tau Aggregation in the Presence of Amyloid $\beta$ . <i>American Journal of Pathology</i> , 2017, 187, 1601-1612.	3.8	167
115	Prediction of cognition in Parkinson's disease with a clinical "genetic score: a longitudinal analysis of nine cohorts. <i>Lancet Neurology</i> , The, 2017, 16, 620-629.	10.2	131
116	Tau at the Crossroads between Neurotoxicity and Neuroprotection. <i>Neuron</i> , 2017, 94, 703-704.	8.1	9
117	Soluble oligomeric amyloid- $\beta$ induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain. <i>Molecular Neurodegeneration</i> , 2017, 12, 27.	10.8	120
118	Absence of Alzheimer Disease Neuropathologic Changes in Eyes of Subjects With Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 376-383.	1.7	50
119	Entorhinal Cortex: Antemortem Cortical Thickness and Postmortem Neurofibrillary Tangles and Amyloid Pathology. <i>American Journal of Neuroradiology</i> , 2017, 38, 961-965.	2.4	30
120	Neurofibrillary Tangle Stage and the Rate of Progression of Alzheimer Symptoms. <i>JAMA Neurology</i> , 2017, 74, 540.	9.0	30
121	Pathological correlations of [ <sup>18</sup> F]AV-1451 imaging in non-Alzheimer tauopathies. <i>Annals of Neurology</i> , 2017, 81, 117-128.	5.3	174
122	Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1451-1459.	2.6	80
123	Poor Performance on a Preoperative Cognitive Screening Test Predicts Postoperative Complications in Older Orthopedic Surgical Patients. <i>Anesthesiology</i> , 2017, 127, 765-774.	2.5	171
124	Activity-Dependent Dysfunction in Visual and Olfactory Sensory Systems in Mouse Models of Down Syndrome. <i>Journal of Neuroscience</i> , 2017, 37, 9880-9888.	3.6	5
125	Polygenic hazard scores in preclinical Alzheimer disease. <i>Annals of Neurology</i> , 2017, 82, 484-488.	5.3	49
126	Local Nucleation of Microtubule Bundles through Tubulin Concentration into a Condensed Tau Phase. <i>Cell Reports</i> , 2017, 20, 2304-2312.	6.4	278



#	ARTICLE	IF	CITATIONS
127	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	21.4	783
128	Isoform- and cell type-specific structure of apolipoprotein E lipoparticles as revealed by a novel Forster resonance energy transfer assay. <i>Journal of Biological Chemistry</i> , 2017, 292, 14720-14729.	3.4	20
129	Trafficking of adeno-associated virus vectors across a model of the blood-brain barrier; a comparative study of transcytosis and transduction using primary human brain endothelial cells. <i>Journal of Neurochemistry</i> , 2017, 140, 216-230.	3.9	97
130	Synaptic phosphorylated $\tau$ -synuclein in dementia with Lewy bodies. <i>Brain</i> , 2017, 140, 3204-3214.	7.6	90
131	Studying tau protein propagation and pathology in the mouse brain using adeno-associated viruses. <i>Methods in Cell Biology</i> , 2017, 141, 307-322.	1.1	23
132	Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score. <i>PLoS Medicine</i> , 2017, 14, e1002258.	8.4	311
133	Characterization of TauC3 antibody and demonstration of its potential to block tau propagation. <i>PLoS ONE</i> , 2017, 12, e0177914.	2.5	36
134	Pathogenic PS1 phosphorylation at Ser367. <i>ELife</i> , 2017, 6, .	6.0	18
135	Amyloid structure exhibits polymorphism on multiple length scales in human brain tissue. <i>Scientific Reports</i> , 2016, 6, 33079.	3.3	48
136	EC $\beta$ : Tau Spreading and Toxicity. <i>Alzheimer's and Dementia</i> , 2016, 12, P269.	0.8	0
137	567. CRISPR-Cas9 Mediated Gene Editing in a Monogenic Form of Alzheimer's Disease. <i>Molecular Therapy</i> , 2016, 24, S226-S227.	8.2	8
138	616. Tailored Expression of a Transgene to Specific Cell Types in the Central Nervous System After Peripheral Injection of AAV9. <i>Molecular Therapy</i> , 2016, 24, S244.	8.2	1
139	Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 164-169.	0.8	82
140	Association Between Genetic Traits for Immune-Mediated Diseases and Alzheimer Disease. <i>JAMA Neurology</i> , 2016, 73, 691.	9.0	151
141	Amyloid $\beta$ oligomerization is associated with the generation of a typical peptide fragment fingerprint. <i>Alzheimer's and Dementia</i> , 2016, 12, 996-1013.	0.8	17
142	Thal Amyloid Stages Do Not Significantly Impact the Correlation Between Neuropathological Change and Cognition in the Alzheimer Disease Continuum. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 516-526.	1.7	67
143	Formation, release, and internalization of stable tau oligomers in cells. <i>Journal of Neurochemistry</i> , 2016, 139, 1163-1174.	3.9	49
144	Episodic memory of odors stratifies Alzheimer biomarkers in normal elderly. <i>Annals of Neurology</i> , 2016, 80, 846-857.	5.3	36

#	ARTICLE	IF	CITATIONS
145	Seed-competent high-molecular-weight tau species accumulates in the cerebrospinal fluid of Alzheimer's disease mouse model and human patients. <i>Annals of Neurology</i> , 2016, 80, 355-367.	5.3	89
146	Tau positron emission tomographic imaging in aging and early Alzheimer disease. <i>Annals of Neurology</i> , 2016, 79, 110-119.	5.3	778
147	Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. <i>Neurology</i> , 2016, 87, 920-926.	1.1	86
148	Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 10186-10191.	7.1	179
149	Non-Fibrillar Oligomeric Amyloid- $\beta^2$ within Synapses. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 787-800.	2.6	65
150	Human tau increases amyloid $\beta^2$ plaque size but not amyloid $\beta^2$ -mediated synapse loss in a novel mouse model of Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2016, 44, 3056-3066.	2.6	81
151	Identification of the novel activity-driven interaction between synaptotagmin 1 and presenilin 1 links calcium, synapse, and amyloid beta. <i>BMC Biology</i> , 2016, 14, 25.	3.8	33
152	Preoperative Cognitive Stratification of Older Elective Surgical Patients: A Cross-Sectional Study. <i>Anesthesia and Analgesia</i> , 2016, 123, 186-192.	2.2	90
153	$\beta$ -Synuclein in Extracellular Vesicles: Functional Implications and Diagnostic Opportunities. <i>Cellular and Molecular Neurobiology</i> , 2016, 36, 437-448.	3.3	53
154	Structural studies on the mechanism of protein aggregation in age related neurodegenerative diseases. <i>Mechanisms of Ageing and Development</i> , 2016, 156, 1-13.	4.6	31
155	Plaque-Associated Local Toxicity Increases over the Clinical Course of Alzheimer Disease. <i>American Journal of Pathology</i> , 2016, 186, 375-384.	3.8	73
156	A novel Alzheimer disease locus located near the gene encoding tau protein. <i>Molecular Psychiatry</i> , 2016, 21, 108-117.	7.9	260
157	3D Visualization of the Temporal and Spatial Spread of Tau Pathology Reveals Extensive Sites of Tau Accumulation Associated with Neuronal Loss and Recognition Memory Deficit in Aged Tau Transgenic Mice. <i>PLoS ONE</i> , 2016, 11, e0159463.	2.5	27
158	THE FEASIBILITY OF AT-HOME IPAD COGNITIVE TESTING FOR USE IN CLINICAL TRIALS. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2016, 3, 1-5.	2.7	39
159	P3-071: A unique high-molecular-weight tau species is involved in propagation and accumulates in the cerebrospinal fluid of Alzheimer's disease patients. , 2015, 11, P644-P644.		0
160	312. Highly-Efficient CNS Transduction With Vesicle-Associated AAV Vector. <i>Molecular Therapy</i> , 2015, 23, S126.	8.2	0
161	Identification of neurotoxic cytokines by profiling Alzheimer's disease tissues and neuron culture viability screening. <i>Scientific Reports</i> , 2015, 5, 16622.	3.3	61
162	IC-P-162: Entorhinal, parahippocampal, and inferior temporal F18-T807 SUVR correlates with CSF total tau and tau T181P in cognitively normal elderly. , 2015, 11, P109-P109.		2

#	ARTICLE	IF	CITATIONS
163	The Influence of Vascular Risk Factors and Stroke on Cognition in Late Life. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 287-293.	1.3	17
164	Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity. <i>EMBO Journal</i> , 2015, 34, 3028-3041.	7.8	112
165	Validating novel tau positron emission tomography tracer $[^{18}\text{F}]\text{AV-1451}$ (T807) on postmortem brain tissue. <i>Annals of Neurology</i> , 2015, 78, 787-800.	5.3	535
166	The Golgi-Localized $\beta$ -Ear-Containing ARF-Binding (GGA) Proteins Alter Amyloid- $\beta$ Precursor Protein (APP) Processing through Interaction of Their GAE Domain with the Beta-Site APP Cleaving Enzyme 1 (BACE1). <i>PLoS ONE</i> , 2015, 10, e0129047.	2.5	17
167	Rarity of the Alzheimer Disease "Protective" APP A673T Variant in the United States. <i>JAMA Neurology</i> , 2015, 72, 209.	9.0	41
168	Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 672-687.	1.7	33
169	Topological analyses in APP/PS1 mice reveal that astrocytes do not migrate to amyloid- $\beta$ plaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 15556-15561.	7.1	39
170	Massachusetts Alzheimer's Disease Research Center: Progress and challenges. <i>Alzheimer's and Dementia</i> , 2015, 11, 1241-1245.	0.8	7
171	P1-027: Improved amyloid pathology contrasting with unexpected memory defects following astrocytic ApoE-2 overexpression in hippocampus of Alzheimer's mice. , 2015, 11, P347-P347.		0
172	O2-06-01: Lack of endogenous tau permits tau spreading and protects against tau toxicity in transgenic mice. , 2015, 11, P186-P186.		0
173	S4-02-02: Modeling braak-like progression of tangles in the medial temporal lobe. , 2015, 11, P258-P258.		0
174	O4-01-04: Entorhinal, parahippocampal, and inferior temporal F18-T807 SUVR correlates with CSF total tau and tau T181P in cognitively normal elderly. , 2015, 11, P267-P267.		1
175	Apolipoprotein E levels and Alzheimer risk. <i>Annals of Neurology</i> , 2015, 77, 204-205.	5.3	8
176	A Food and Drug Administration-approved Asthma Therapeutic Agent Impacts Amyloid $\beta$ in the Brain in a Transgenic Model of Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2015, 290, 1966-1978.	3.4	65
177	APOE $\epsilon$ 2 is associated with milder clinical and pathological Alzheimer disease. <i>Annals of Neurology</i> , 2015, 77, 917-929.	5.3	132
178	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , 2015, 138, 2701-2715.	7.6	109
179	Role of Apolipoprotein E in $\beta$ -Amyloidogenesis. <i>Journal of Biological Chemistry</i> , 2015, 290, 15163-15174.	3.4	46
180	Inhibition of amyloid- $\beta$ plaque formation by $\beta$ -synuclein. <i>Nature Medicine</i> , 2015, 21, 802-807.	30.7	97

#	ARTICLE	IF	CITATIONS
181	Oxidative stress and lipid peroxidation are upstream of amyloid pathology. <i>Neurobiology of Disease</i> , 2015, 84, 109-119.	4.4	118
182	A highly sensitive novel immunoassay specifically detects low levels of soluble A $\beta$ oligomers in human cerebrospinal fluid. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 14.	6.2	78
183	Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2015, 3, 14.	5.2	176
184	PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. <i>Acta Neuropathologica</i> , 2015, 129, 757-762.	7.7	139
185	Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease. <i>Circulation</i> , 2015, 131, 2061-2069.	1.6	145
186	Retinal blood flow in mild cognitive impairment and Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 144-151.	2.4	108
187	Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain. <i>Nature Communications</i> , 2015, 6, 8490.	12.8	283
188	Association between $\alpha$ -synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. <i>Brain</i> , 2015, 138, 2659-2671.	7.6	69
189	Alzheimer dementia with sparse amyloid—AD mimic or variant?. <i>Nature Reviews Neurology</i> , 2015, 11, 674-675.	10.1	2
190	Carboxy Terminus Heat Shock Protein 70 Interacting Protein Reduces Tau-Associated Degenerative Changes. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 937-947.	2.6	29
191	At the interface of sensory and motor dysfunctions and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 70-98.	0.8	420
192	RNA Aptamer Probes as Optical Imaging Agents for the Detection of Amyloid Plaques. <i>PLoS ONE</i> , 2014, 9, e89901.	2.5	37
193	Direct Visualization of CHIP-Mediated Degradation of Alpha-Synuclein In Vivo: Implications for PD Therapeutics. <i>PLoS ONE</i> , 2014, 9, e92098.	2.5	14
194	Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2014, 2, 146.	5.2	79
195	Regional Cortical Thinning and Cerebrospinal Biomarkers Predict Worsening Daily Functioning Across the Alzheimer's Disease Spectrum. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 719-728.	2.6	51
196	The Role of Clusterin in Amyloid- $\beta$ -Associated Neurodegeneration. <i>JAMA Neurology</i> , 2014, 71, 180.	9.0	66
197	Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer's Disease and Related Dementias. <i>PLoS Genetics</i> , 2014, 10, e1004606.	3.5	305
198	Failure analysis of clinical trials to test the amyloid hypothesis. <i>Annals of Neurology</i> , 2014, 76, 159-161.	5.3	14

#	ARTICLE	IF	CITATIONS
199	Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 510-514.	7.1	170
200	Tau pathology does not affect experience-driven single-neuron and network-wide Arc/Arg3.1 responses. Acta Neuropathologica Communications, 2014, 2, 63.	5.2	24
201	A Novel <i>GRN</i> Mutation ( <i>GRN</i> c.708+6_+9delTGAC) in Frontotemporal Lobar Degeneration With TDP-43 <sup>+</sup> Positive Inclusions. Journal of Neuro pathology and Experimental Neurology, 2014, 73, 467-473.	1.7	7
202	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	9.0	166
203	<i>APOE</i> Genotype and Brain Development. JAMA Neurology, 2014, 71, 7.	9.0	6
204	Regulation of Dynamin Oligomerization in Cells: The Role of Dynamin-Actin Interactions and Its <i>GTPase</i> Activity. Traffic, 2014, 15, 819-838.	2.7	45
205	Structural Interactions between Inhibitor and Substrate Docking Sites Give Insight into Mechanisms of Human PS1 Complexes. Structure, 2014, 22, 125-135.	3.3	56
206	Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Annals of Neurology, 2014, 75, 597-601.	5.3	90
207	Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy. Neuroscience Letters, 2014, 562, 63-68.	2.1	33
208	Subjective Cognitive Concerns and Neuropsychiatric Predictors of Progression to the Early Clinical Stages of Alzheimer Disease. American Journal of Geriatric Psychiatry, 2014, 22, 1642-1651.	1.2	167
209	Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer <sup>TM</sup> s disease model. Acta Neuropathologica, 2014, 127, 257-270.	7.7	88
210	Anti-ApoE Antibody Given after Plaque Onset Decreases A $\beta$ Accumulation and Improves Brain Function in a Mouse Model of A $\beta$ Amyloidosis. Journal of Neuroscience, 2014, 34, 7281-7292.	3.6	102
211	Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathologica, 2014, 128, 755-766.	7.7	1,060
212	Measuring Caspase Activity In Vivo. Methods in Enzymology, 2014, 544, 251-269.	1.0	11
213	Tau Propagation, Different Tau Phenotypes, and Prion-like Properties of Tau. Neuron, 2014, 82, 1189-1190.	8.1	40
214	The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer <sup>TM</sup> s Disease. Neuron, 2014, 82, 756-771.	8.1	862
215	High prevalence of <i>NMDA</i> receptor IgA/IgM antibodies in different dementia types. Annals of Clinical and Translational Neurology, 2014, 1, 822-832.	3.7	114
216	DT-01-02: TEMPORAL NEOCORTICAL TAU DEPOSITION MEASURED WITH PET IS ASSOCIATED WITH LONGITUDINAL DECLINE IN MEMORY PERFORMANCE AMONG CLINICALLY NORMAL ELDERLY. , 2014, 10, P280-P280.		0

#	ARTICLE	IF	CITATIONS
217	P1-025: CONSEQUENCES OF APOE2 OVEREXPRESSION IN ASTROCYTES IN AN ALZHEIMER'S DISEASE MOUSE MODEL. , 2014, 10, P313-P313.		0
218	P3-126: EXPLORATION OF PLASMA BIOMARKERS FOR ALZHEIMER'S DISEASE USING ISOTOPIC TANDEM MASS TAGS AND A COMBINED DIRECTED/DATA-DEPENDENT ACQUISITION NLC-MS/MS METHOD. , 2014, 10, P674-P674.		2
219	O4-03-05: NLRP1 INFLAMMASOME REGULATES CASPASE-1-MEDIATED CASPASE-6 ACTIVATION IN HUMAN NEURONS. , 2014, 10, P255-P255.		0
220	O4-09-04: UNRAVELING THE ROLE OF APOLIPOPROTEIN E IN AGE- AND ABETA-RELATED NEURONAL DYSFUNCTION. , 2014, 10, P269-P269.		0
221	A Phenotypic Change But Not Proliferation Underlies Glial Responses in Alzheimer Disease. American Journal of Pathology, 2013, 182, 2332-2344.	3.8	131
222	Studying synapses in human brain with array tomography and electron microscopy. Nature Protocols, 2013, 8, 1366-1380.	12.0	95
223	Reversal of Neurofibrillary Tangles and Tau-Associated Phenotype in the rTgTauEC Model of Early Alzheimer's Disease. Journal of Neuroscience, 2013, 33, 13300-13311.	3.6	42
224	Clustering of plaques contributes to plaque growth in a mouse model of Alzheimer's disease. Acta Neuropathologica, 2013, 126, 179-188.	7.7	27
225	The Challenge of Connecting the Dots in the B.R.A.I.N.. Neuron, 2013, 80, 270-274.	8.1	73
226	Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain, 2013, 136, 2510-2526.	7.6	294
227	Neuronal activity and secreted amyloid $\beta^2$ lead to altered amyloid $\beta^2$ precursor protein and presenilin 1 interactions. Neurobiology of Disease, 2013, 50, 127-134.	4.4	32
228	Mouse Gender Influences Brain Transduction by Intravascularly Administered AAV9. Molecular Therapy, 2013, 21, 1470-1471.	8.2	33
229	Gene Transfer of Human <i>ApoE</i> Isoforms Results in Differential Modulation of Amyloid Deposition and Neurotoxicity in Mouse Brain. Science Translational Medicine, 2013, 5, 212ra161.	12.4	135
230	Endogenous Tau Aggregates in Oligodendrocytes of rTg4510 Mice Induced by Human P301L Tau. Journal of Alzheimer's Disease, 2013, 38, 589-600.	2.6	11
231	Tau-amyloid interactions in the rTgTauEC model of early Alzheimer's disease suggest amyloid-induced disruption of axonal projections and exacerbated axonal pathology. Journal of Comparative Neurology, 2013, 521, 4236-4248.	1.6	28
232	Human LILRB2 Is a $\beta^2$ -Amyloid Receptor and Its Murine Homolog PirB Regulates Synaptic Plasticity in an Alzheimer's Model. Science, 2013, 341, 1399-1404.	12.6	335
233	Mechanisms of Protein Seeding in Neurodegenerative Diseases. JAMA Neurology, 2013, 70, 304.	9.0	195
234	O2-01-01: Neurofibrillary tangles remain functionally integrated in cortical networks. , 2013, 9, P314-P314.		0

#	ARTICLE	IF	CITATIONS
235	Synaptic alterations in the rTg4510 mouse model of tauopathy. <i>Journal of Comparative Neurology</i> , 2013, 521, 1334-1353.	1.6	98
236	Alzheimer's Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta. <i>Neuron</i> , 2013, 78, 631-643.	8.1	776
237	Brain interstitial oligomeric amyloid $\beta^2$ increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease. <i>FASEB Journal</i> , 2013, 27, 3239-3248.	0.5	57
238	Engulfment adaptor phosphotyrosine-binding-domain-containing 1 (GULP1) is a nucleocytoplasmic shuttling protein and is transactivationally active together with low-density lipoprotein receptor-related protein 1 (LRP1). <i>Biochemical Journal</i> , 2013, 450, 333-343.	3.7	6
239	Examination of the Clinicopathologic Continuum of Alzheimer Disease in the Autopsy Cohort of the National Alzheimer Coordinating Center. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 1182-1192.	1.7	89
240	Propagation of tau pathology in Alzheimer's disease: identification of novel therapeutic targets. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 49.	6.2	84
241	Differential Relationships of Reactive Astrocytes and Microglia to Fibrillar Amyloid Deposits in Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 462-471.	1.7	163
242	Improved Design of Prodromal Alzheimer's Disease Trials through Cohort Enrichment and Surrogate Endpoints. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 475-486.	2.6	6
243	EM Structure of the Ectodomain of Integrin CD11b/CD18 and Localization of Its Ligand-Binding Site Relative to the Plasma Membrane. <i>PLoS ONE</i> , 2013, 8, e57951.	2.5	11
244	A Luminex Assay Detects Amyloid $\beta^2$ Oligomers in Alzheimer's Disease Cerebrospinal Fluid. <i>PLoS ONE</i> , 2013, 8, e67898.	2.5	59
245	Tau Causes Synapse Loss without Disrupting Calcium Homeostasis in the rTg4510 Model of Tauopathy. <i>PLoS ONE</i> , 2013, 8, e80834.	2.5	38
246	Distinct Dendritic Spine and Nuclear Phases of Calcineurin Activation after Exposure to Amyloid- $\beta^2$ Revealed by a Novel Fluorescence Resonance Energy Transfer Assay. <i>Journal of Neuroscience</i> , 2012, 32, 5298-5309.	3.6	54
247	Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid- $\beta^2$ . <i>Brain</i> , 2012, 135, 2155-2168.	7.6	268
248	Synaptic Plasticity Defect Following Visual Deprivation in Alzheimer's Disease Model Transgenic Mice. <i>Journal of Neuroscience</i> , 2012, 32, 8004-8011.	3.6	52
249	The SIST-M. <i>Alzheimer Disease and Associated Disorders</i> , 2012, 26, 225-231.	1.3	15
250	Stable Size Distribution of Amyloid Plaques Over the Course of Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 694-701.	1.7	41
251	Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 362-381.	1.7	1,599
252	Alpha-synuclein aggregation involves a bafilomycin A-sensitive autophagy pathway. <i>Autophagy</i> , 2012, 8, 754-766.	9.1	111



#	ARTICLE	IF	CITATIONS
253	National Institute on Aging's Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2012, 8, 1-13.	0.8	1,968
254	Engulfment adapter PTB domain containing 1 interacts with and affects processing of the amyloid- $\beta^2$ precursor protein. <i>Neurobiology of Aging</i> , 2012, 33, 732-743.	3.1	14
255	Propagation of Tau Pathology in a Model of Early Alzheimer's Disease. <i>Neuron</i> , 2012, 73, 685-697.	8.1	1,191
256	A $\beta^2$ alters the connectivity of olfactory neurons in the absence of amyloid plaques in vivo. <i>Nature Communications</i> , 2012, 3, 1009.	12.8	71
257	Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid $\beta^2$ Peptide. <i>Journal of Neuroscience</i> , 2012, 32, 15181-15192.	3.6	219
258	Orchestrated experience-driven Arc responses are disrupted in a mouse model of Alzheimer's disease. <i>Nature Neuroscience</i> , 2012, 15, 1422-1429.	14.8	108
259	Soluble forms of tau are toxic in Alzheimer's disease. <i>Translational Neuroscience</i> , 2012, 3, 223-233.	1.4	185
260	The Synaptic Accumulation of Hyperphosphorylated Tau Oligomers in Alzheimer Disease Is Associated With Dysfunction of the Ubiquitin-Proteasome System. <i>American Journal of Pathology</i> , 2012, 181, 1426-1435.	3.8	369
261	Inhibition of the NFAT Pathway Alleviates Amyloid Beta Neurotoxicity in a Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2012, 32, 3176-3192.	3.6	92
262	Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology. <i>Nature Reviews Neuroscience</i> , 2012, 13, 395-406.	10.2	218
263	Meta-analysis of Parkinson's Disease: Identification of a novel locus, <i>RIT2</i> . <i>Annals of Neurology</i> , 2012, 71, 370-384.	5.3	264
264	National Institute on Aging's Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. <i>Acta Neuropathologica</i> , 2012, 123, 1-11.	7.7	2,002
265	Calcineurin activation causes retinal ganglion cell degeneration. <i>Molecular Vision</i> , 2012, 18, 2828-38.	1.1	10
266	Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18837-18842.	7.1	228
267	Neuropathological Alterations in Alzheimer Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2011, 1, a006189-a006189.	6.2	2,365
268	Heat shock protein 70 modulates toxic extracellular $\alpha$ -synuclein oligomers and rescues trans-synaptic toxicity. <i>FASEB Journal</i> , 2011, 25, 326-336.	0.5	276
269	Reactive Glia not only Associates with Plaques but also Parallels Tangles in Alzheimer's Disease. <i>American Journal of Pathology</i> , 2011, 179, 1373-1384.	3.8	379
270	Tau Accumulation Causes Mitochondrial Distribution Deficits in Neurons in a Mouse Model of Tauopathy and in Human Alzheimer's Disease Brain. <i>American Journal of Pathology</i> , 2011, 179, 2071-2082.	3.8	224



#	ARTICLE	IF	CITATIONS
271	Calcineurin inhibition with systemic FK506 treatment increases dendritic branching and dendritic spine density in healthy adult mouse brain. <i>Neuroscience Letters</i> , 2011, 487, 260-263.	2.1	40
272	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 263-269.	0.8	12,681
273	O1-05-01: APOE4 plays a role in Abeta-mediated synapse loss in Alzheimer's disease. , 2011, 7, S103-S104.		0
274	Plasma $\beta$ -Amyloid Linked to Cognitive Decline. <i>Archives of Neurology</i> , 2011, 68, 799-801.	4.5	0
275	Apolipoprotein E: Isoform Specific Differences in Tertiary Structure and Interaction with Amyloid- $\beta$ in Human Alzheimer Brain. <i>PLoS ONE</i> , 2011, 6, e14586.	2.5	66
276	Ubiquitinylation of $\beta$ -Synuclein by Carboxyl Terminus Hsp70-Interacting Protein (CHIP) Is Regulated by Bcl-2-Associated Athanogene 5 (BAG5). <i>PLoS ONE</i> , 2011, 6, e14695.	2.5	119
277	Soluble tau Species, Not Neurofibrillary Aggregates, Disrupt Neural System Integration in a tau Transgenic Model. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 588-595.	1.7	74
278	Brain Oligomeric $\beta$ -Amyloid but Not Total Amyloid Plaque Burden Correlates With Neuronal Loss and Astrocyte Inflammatory Response in Amyloid Precursor Protein/Tau Transgenic Mice. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 360-376.	1.7	111
279	Alzheimer's Disease-Associated Ubiquitin-1 Regulates Presenilin-1 Accumulation and Aggresome Formation. <i>Traffic</i> , 2011, 12, 330-348.	2.7	69
280	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. <i>Nature Genetics</i> , 2011, 43, 436-441.	21.4	1,676
281	Caspase activation without apoptosis: insight into $\beta$ initiation of neurodegeneration. <i>Nature Neuroscience</i> , 2011, 14, 5-6.	14.8	38
282	Calcineurin inhibition with FK506 ameliorates dendritic spine density deficits in plaque-bearing Alzheimer model mice. <i>Neurobiology of Disease</i> , 2011, 41, 650-654.	4.4	80
283	Are Tangles as Toxic as They Look?. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 438-444.	2.3	93
284	Association of <i>SNCA</i> with Parkinson: Replication in the Harvard NeuroDiscovery Center Biomarker Study. <i>Movement Disorders</i> , 2011, 26, 2283-2286.	3.9	21
285	Amyloid- $\beta$ associated volume loss occurs only in the presence of phospho- $\tau$ . <i>Annals of Neurology</i> , 2011, 70, 657-661.	5.3	109
286	LRAD3, A Novel Low-Density Lipoprotein Receptor Family Member That Modulates Amyloid Precursor Protein Trafficking. <i>Journal of Neuroscience</i> , 2011, 31, 10836-10846.	3.6	39
287	Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2011, 12, 430-438.	2.1	27
288	Novel Progranulin Mutation Detected in 2 Patients With FTL. <i>Alzheimer Disease and Associated Disorders</i> , 2011, 25, 173-178.	1.3	10

#	ARTICLE	IF	CITATIONS
289	Amyloid-Dependent and Amyloid-Independent Stages of Alzheimer Disease. <i>Archives of Neurology</i> , 2011, 68, 1062.	4.5	173
290	Characterization of Oligomer Formation of Amyloid- $\beta^2$ Peptide Using a Split-luciferase Complementation Assay. <i>Journal of Biological Chemistry</i> , 2011, 286, 27081-27091.	3.4	65
291	The Structured Interview & Scoring Tool—Massachusetts Alzheimer's Disease Research Center (SIST-M). <i>Archives of Neurology</i> , 2011, 68, 343-50.	4.5	10
292	Distinct Roles <i>In Vivo</i> for the Ubiquitin-Proteasome System and the Autophagy-Lysosomal Pathway in the Degradation of $\beta$ -Synuclein. <i>Journal of Neuroscience</i> , 2011, 31, 14508-14520.	3.6	311
293	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. , 2011, 7, 263.		1
294	Preoperative Cognitive Assessment of the Elderly Surgical Patient. <i>Anesthesiology</i> , 2011, 114, 1265-1268.	2.5	63
295	Caspase activation precedes and leads to tangles. <i>Nature</i> , 2010, 464, 1201-1204.	27.8	463
296	Pro-cathepsin D interacts with the extracellular domain of the $\beta$ chain of LRP1 and promotes LRP1-dependent fibroblast outgrowth. <i>Journal of Cell Science</i> , 2010, 123, 3336-3346.	2.0	49
297	Effects of Simvastatin on Cholesterol Metabolism and Alzheimer Disease Biomarkers. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 220-226.	1.3	57
298	Brain-Permeable Small-Molecule Inhibitors of Hsp90 Prevent $\beta$ -Synuclein Oligomer Formation and Rescue $\beta$ -Synuclein-Induced Toxicity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 332, 849-857.	2.5	162
299	Beneficial effect of human anti-amyloid- $\beta^2$ active immunization on neurite morphology and tau pathology. <i>Brain</i> , 2010, 133, 1312-1327.	7.6	138
300	Converse modulation of toxic $\beta$ -synuclein oligomers in living cells by N <sup>ε</sup> -benzylidene-benzohydrazide derivatives and ferric iron. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 461-466.	2.1	52
301	Antioxidants have a rapid and long-lasting effect on neuritic abnormalities in APP:PS1 mice. <i>Neurobiology of Aging</i> , 2010, 31, 2058-2068.	3.1	32
302	PL-05-01: A transgenic model of the earliest stage of Alzheimer's disease. , 2010, 6, S165-S165.		0
303	Amyloid $\beta^2$ Induces the Morphological Neurodegenerative Triad of Spine Loss, Dendritic Simplification, and Neuritic Dystrophies through Calcineurin Activation. <i>Journal of Neuroscience</i> , 2010, 30, 2636-2649.	3.6	328
304	The Alzheimer's Disease-Associated Amyloid $\beta^2$ -Protein Is an Antimicrobial Peptide. <i>PLoS ONE</i> , 2010, 5, e9505.	2.5	868
305	In Vivo Imaging of $\beta$ -Synuclein in Mouse Cortex Demonstrates Stable Expression and Differential Subcellular Compartment Mobility. <i>PLoS ONE</i> , 2010, 5, e10589.	2.5	49
306	Synchronous Hyperactivity and Intercellular Calcium Waves in Astrocytes in Alzheimer Mice. <i>Science</i> , 2009, 323, 1211-1215.	12.6	606

#	ARTICLE	IF	CITATIONS
307	$\beta$ -Secretase Heterogeneity in the Aph1 Subunit: Relevance for Alzheimer's Disease. <i>Science</i> , 2009, 324, 639-642.	12.6	233
308	The Effects of Amyloid Precursor Protein on Postsynaptic Composition and Activity. <i>Journal of Biological Chemistry</i> , 2009, 284, 8495-8506.	3.4	101
309	Tyrosine and serine phosphorylation of $\tau$ have opposing effects on neurotoxicity and soluble oligomer formation. <i>Journal of Clinical Investigation</i> , 2009, 119, 3257-65.	8.2	158
310	Rapid Progression from Mild Cognitive Impairment to Alzheimer's Disease in Subjects with Elevated Levels of Tau in Cerebrospinal Fluid and the $\epsilon$ /APOE $\epsilon$ /Genotype. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 458-464.	1.5	119
311	A Reporter of Local Dendritic Translocation Shows Plaque-Related Loss of Neural System Function in APP-Transgenic Mice. <i>Journal of Neuroscience</i> , 2009, 29, 12636-12640.	3.6	54
312	Tangle-Bearing Neurons Survive Despite Disruption of Membrane Integrity in a Mouse Model of Tauopathy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 757-761.	1.7	69
313	Interaction of Reelin with Amyloid Precursor Protein Promotes Neurite Outgrowth. <i>Journal of Neuroscience</i> , 2009, 29, 7459-7473.	3.6	182
314	Oligomeric amyloid $\beta$ associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 4012-4017.	7.1	734
315	Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease. <i>Neurobiology of Disease</i> , 2009, 33, 213-220.	4.4	66
316	A single dose of passive immunotherapy has extended benefits on synapses and neurites in an Alzheimer's disease mouse model. <i>Brain Research</i> , 2009, 1280, 178-185.	2.2	20
317	Effects of Ubiquilin 1 on the Unfolded Protein Response. <i>Journal of Molecular Neuroscience</i> , 2009, 38, 19-30.	2.3	28
318	Adult Onset Leukodystrophy with Neuroaxonal Spheroids: Clinical, Neuroimaging and Neuropathologic Observations. <i>Brain Pathology</i> , 2009, 19, 39-47.	4.1	90
319	N-cadherin-based adhesion enhances $\beta$ release and decreases $\beta$ <sub>42/40</sub> ratio. <i>Journal of Neurochemistry</i> , 2009, 108, 350-360.	3.9	22
320	Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system. <i>Journal of Neurochemistry</i> , 2009, 109, 838-845.	3.9	91
321	Differential effect of three-repeat and four-repeat tau on mitochondrial axonal transport. <i>Journal of Neurochemistry</i> , 2009, 111, 417-427.	3.9	123
322	Performance Characteristics of Plasma Amyloid- $\beta$ 40 and 42 Assays. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 277-285.	2.6	28
323	Tau pathophysiology in neurodegeneration: a tangled issue. <i>Trends in Neurosciences</i> , 2009, 32, 150-159.	8.6	284
324	A highly insoluble state of $\beta$ similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice. <i>Neurobiology of Aging</i> , 2009, 30, 1393-1405.	3.1	79

#	ARTICLE	IF	CITATIONS
325	Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia. <i>Neuron</i> , 2009, 63, 178-188.	8.1	899
326	Mutations in amyloid precursor protein affect its interactions with presenilin/ $\beta$ -secretase. <i>Molecular and Cellular Neurosciences</i> , 2009, 41, 166-174.	2.2	45
327	Crystal structure of the complete integrin $\alpha$ <sub>5</sub> $\beta$ <sub>3</sub> ectodomain plus an $\alpha$ <sub>5</sub> / $\beta$ <sub>2</sub> transmembrane fragment. <i>Journal of Cell Biology</i> , 2009, 186, 589-600.	5.2	163
328	Predicting the location of entorhinal cortex from MRI. <i>NeuroImage</i> , 2009, 47, 8-17.	4.2	94
329	Mild cholesterol depletion reduces amyloid $\beta$ production by impairing APP trafficking to the cell surface. <i>Journal of Neurochemistry</i> , 2009, 110, 220-230.	3.9	60
330	$\alpha$ -Synuclein S129 Phosphorylation Mutants Do Not Alter Nigrostriatal Toxicity in a Rat Model of Parkinson Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 515-524.	1.7	111
331	Dopamine-Induced Conformational Changes in Alpha-Synuclein. <i>PLoS ONE</i> , 2009, 4, e6906.	2.5	59
332	Allosteric Modulation of PS1/ $\beta$ -Secretase Conformation Correlates with Amyloid $\beta$ <sub>42</sub> / $\beta$ <sub>40</sub> Ratio. <i>PLoS ONE</i> , 2009, 4, e7893.	2.5	73
333	Rapid appearance and local toxicity of amyloid- $\beta$ plaques in a mouse model of Alzheimer's disease. <i>Nature</i> , 2008, 451, 720-724.	27.8	916
334	Heparan Sulfate Accumulation with $\beta$ Amyloid Deposits in Alzheimer's Disease and Tg2576 Mice is Contributed by Glial Cells. <i>Brain Pathology</i> , 2008, 18, 548-561.	4.1	71
335	Transcriptional dysregulation in a transgenic model of Parkinson disease. <i>Neurobiology of Disease</i> , 2008, 29, 515-528.	4.4	62
336	Neuropathology of Alzheimer's Disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 233-243.	1.8	44
337	<i>In Vivo</i> Imaging Reveals Dissociation between Caspase Activation and Acute Neuronal Death in Tangle-Bearing Neurons. <i>Journal of Neuroscience</i> , 2008, 28, 862-867.	3.6	132
338	The LDL receptor-related protein can form homo-dimers in neuronal cells. <i>Neuroscience Letters</i> , 2008, 442, 91-95.	2.1	6
339	$\beta$ Amyloid Plaques Lead to Aberrant Regulation of Calcium Homeostasis <i>In Vivo</i> Resulting in Structural and Functional Disruption of Neuronal Networks. <i>Neuron</i> , 2008, 59, 214-225.	8.1	551
340	Rapid Microglial Response Around Amyloid Pathology after Systemic Anti- $\beta$ Amyloid Antibody Administration in PDAPP Mice. <i>Journal of Neuroscience</i> , 2008, 28, 14156-14164.	3.6	136
341	Fyn Modulation of Dab1 Effects on Amyloid Precursor Protein and ApoE Receptor 2 Processing. <i>Journal of Biological Chemistry</i> , 2008, 283, 6288-6299.	3.4	47
342	CHIP Targets Toxic $\alpha$ -Synuclein Oligomers for Degradation. <i>Journal of Biological Chemistry</i> , 2008, 283, 17962-17968.	3.4	155

#	ARTICLE	IF	CITATIONS
343	The nuclear membrane organization of leukotriene synthesis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20434-20439.	7.1	90
344	Plasma $\beta$ Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men. Archives of Neurology, 2008, 65, 256-63.	4.5	100
345	Plasma Amyloid $\beta$ -Protein and C-reactive Protein in Relation to the Rate of Progression of Alzheimer Disease. Archives of Neurology, 2008, 65, 776-85.	4.5	84
346	Distinct Pools of $\beta$ -Amyloid in Alzheimer Disease-Affected Brain. Archives of Neurology, 2008, 65, 906-12.	4.5	88
347	Preservation of Neuronal Number Despite Age-Related Cortical Brain Atrophy in Elderly Subjects Without Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2008, 67, 1205-1212.	1.7	164
348	TAR-DNA Binding Protein 43 in Pick Disease. Journal of Neuropathology and Experimental Neurology, 2008, 67, 62-67.	1.7	72
349	Shorter Telomeres May Mark Early Risk of Dementia: Preliminary Analysis of 62 Participants from the Nurses' Health Study. PLoS ONE, 2008, 3, e1590.	2.5	87
350	Formation of Toxic Oligomeric $\alpha$ -Synuclein Species in Living Cells. PLoS ONE, 2008, 3, e1867.	2.5	354
351	In reply to Zou et al. "New amyloid plaques or a game of hide-and-seek?" International Journal of Biological Sciences, 2008, 4, 245-245.	6.4	0
352	Decreased Catalytic Activity of the Insulin-degrading Enzyme in Chromosome 10-Linked Alzheimer Disease Families. Journal of Biological Chemistry, 2007, 282, 7825-7832.	3.4	89
353	Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain, 2007, 130, 2310-2319.	7.6	164
354	Molecular Imaging With Pittsburgh Compound B Confirmed at Autopsy. Archives of Neurology, 2007, 64, 431.	4.5	326
355	Plasma $\beta$ Levels Do Not Reflect Brain $\beta$ Levels. Journal of Neuropathology and Experimental Neurology, 2007, 66, 264-271.	1.7	62
356	Pharmacological inhibition of PARP-1 reduces $\alpha$ -synuclein- and MPP <sup>+</sup> -induced cytotoxicity in Parkinson's disease in vitro models. Biochemical and Biophysical Research Communications, 2007, 357, 596-602.	2.1	67
357	Angiotensin II protects against $\alpha$ -synuclein toxicity and reduces protein aggregation in vitro. Biochemical and Biophysical Research Communications, 2007, 363, 846-851.	2.1	25
358	The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neuroscience Letters, 2007, 427, 127-131.	2.1	112
359	Impaired Spine Stability Underlies Plaque-Related Spine Loss in an Alzheimer's Disease Mouse Model. American Journal of Pathology, 2007, 171, 1304-1311.	3.8	179
360	Sirtuin 2 Inhibitors Rescue $\alpha$ -Synuclein-Mediated Toxicity in Models of Parkinson's Disease. Science, 2007, 317, 516-519.	12.6	995

#	ARTICLE	IF	CITATIONS
361	Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. <i>Nature Cell Biology</i> , 2007, 9, 139-148.	10.3	399
362	Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. <i>Journal of Neurochemistry</i> , 2007, 100, 070214184024010-???	3.9	164
363	Single molecule profiling of tau gene expression in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2007, 103, 1228-1236.	3.9	60
364	Expression of APP pathway mRNAs and proteins in Alzheimer's disease. <i>Brain Research</i> , 2007, 1161, 116-123.	2.2	159
365	A limited role for microglia in antibody mediated plaque clearance in APP mice. <i>Neurobiology of Disease</i> , 2007, 28, 286-292.	4.4	40
366	Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains. <i>Acta Neuropathologica</i> , 2007, 114, 471-479.	7.7	36
367	Pharmacological promotion of inclusion formation: A therapeutic approach for Huntington's and Parkinson's diseases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 4246-4251.	7.1	244
368	Region-specific Dissociation of Neuronal Loss and Neurofibrillary Pathology in a Mouse Model of Tauopathy. <i>American Journal of Pathology</i> , 2006, 168, 1598-1607.	3.8	349
369	An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. <i>NeuroImage</i> , 2006, 31, 968-980.	4.2	10,125
370	Detection of presenilin-1 homodimer formation in intact cells using fluorescent lifetime imaging microscopy. <i>Biochemical and Biophysical Research Communications</i> , 2006, 340, 668-674.	2.1	24
371	Fluorescence lifetime imaging microscopy (FLIM) detects stimulus-dependent phosphorylation of the low density lipoprotein receptor-related protein (LRP) in primary neurons. <i>Biochemical and Biophysical Research Communications</i> , 2006, 349, 24-30.	2.1	13
372	Small heat shock proteins protect against $\beta$ -synuclein-induced toxicity and aggregation. <i>Biochemical and Biophysical Research Communications</i> , 2006, 351, 631-638.	2.1	180
373	Preclinical characterization of amyloid imaging probes with multiphoton microscopy. <i>Journal of Alzheimer's Disease</i> , 2006, 9, 401-407.	2.6	11
374	Relation of Quantitative Indexes of Concurrent $\beta$ -Synuclein Abnormalities to Clinical Outcome in Autopsy-Proven Alzheimer Disease. <i>Archives of Neurology</i> , 2006, 63, 226.	4.5	12
375	Plaque-Derived Oxidative Stress Mediates Distorted Neurite Trajectories in the Alzheimer Mouse Model. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 1082-1089.	1.7	85
376	Coordinated Expression of Caspase 8, 3 and 7 mRNA in Temporal Cortex of Alzheimer Disease: Relationship to Formic Acid Extractable $A\beta_{42}$ Levels. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 508-515.	1.7	54
377	Can the immune system fight Alzheimer disease?. <i>Nature Medicine</i> , 2006, 12, 755-756.	30.7	3
378	Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. <i>EMBO Journal</i> , 2006, 25, 1860-1870.	7.8	161



#	ARTICLE	IF	CITATIONS
379	Physical and functional connection between auxilin and dynamin during endocytosis. <i>EMBO Journal</i> , 2006, 25, 4163-4174.	7.8	29
380	Clinical and biochemical correlates of insoluble $\beta$ -synuclein in dementia with Lewy bodies. <i>Acta Neuropathologica</i> , 2006, 111, 101-108.	7.7	55
381	No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer's disease brain. <i>Acta Neuropathologica</i> , 2006, 112, 439-449.	7.7	41
382	Interaction of the Cytosolic Domains of sorLA/LR11 with the Amyloid Precursor Protein (APP) and $\beta$ -Secretase $\beta$ -Site APP-Cleaving Enzyme. <i>Journal of Neuroscience</i> , 2006, 26, 418-428.	3.6	162
383	Dopamine D <sub>1</sub> Activation Potentiates Striatal NMDA Receptors by Tyrosine Phosphorylation-Dependent Subunit Trafficking. <i>Journal of Neuroscience</i> , 2006, 26, 4690-4700.	3.6	193
384	GGA1 Acts as a Spatial Switch Altering Amyloid Precursor Protein Trafficking and Processing. <i>Journal of Neuroscience</i> , 2006, 26, 9913-9922.	3.6	56
385	Interaction between Presenilin 1 and Ubiquilin 1 as Detected by Fluorescence Lifetime Imaging Microscopy and a High-throughput Fluorescent Plate Reader. <i>Journal of Biological Chemistry</i> , 2006, 281, 26400-26407.	3.4	21
386	Detection of novel intracellular $\alpha$ -synuclein oligomeric species by fluorescence lifetime imaging. <i>FASEB Journal</i> , 2006, 20, 2050-2057.	0.5	82
387	Ubiquilin 1 Modulates Amyloid Precursor Protein Trafficking and $A\beta$ Secretion. <i>Journal of Biological Chemistry</i> , 2006, 281, 32240-32253.	3.4	90
388	Kinetics of Cerebral Amyloid Angiopathy Progression in a Transgenic Mouse Model of Alzheimer Disease. <i>Journal of Neuroscience</i> , 2006, 26, 365-371.	3.6	69
389	Alpha-Synuclein and Chaperones in Dementia With Lewy Bodies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 1058-1066.	1.7	55
390	APP substitutions V715F and L720P alter PS1 conformation and differentially affect $A\beta$ and AICD generation. <i>Journal of Neurochemistry</i> , 2005, 95, 446-456.	3.9	30
391	In Vivo Optical Imaging of Amyloid Aggregates in Brain: Design of Fluorescent Markers. <i>Angewandte Chemie - International Edition</i> , 2005, 44, 5452-5456.	13.8	303
392	Dendritic Spine Abnormalities in Amyloid Precursor Protein Transgenic Mice Demonstrated by Gene Transfer and Intravital Multiphoton Microscopy. <i>Journal of Neuroscience</i> , 2005, 25, 7278-7287.	3.6	524
393	Autoantibodies to Redox-modified Oligomeric $A\beta$ Are Attenuated in the Plasma of Alzheimer's Disease Patients. <i>Journal of Biological Chemistry</i> , 2005, 280, 17458-17463.	3.4	83
394	BACE Is Degraded via the Lysosomal Pathway. <i>Journal of Biological Chemistry</i> , 2005, 280, 32499-32504.	3.4	149
395	Family-Based Association between Alzheimer's Disease and Variants in <i>UBQLN1</i> . <i>New England Journal of Medicine</i> , 2005, 352, 884-894.	27.0	232
396	Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 13461-13466.	7.1	582

#	ARTICLE	IF	CITATIONS
397	The Low Density Lipoprotein Receptor-related Protein (LRP) Is a Novel $\beta$ -Secretase (BACE1) Substrate. <i>Journal of Biological Chemistry</i> , 2005, 280, 17777-17785.	3.4	228
398	The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. <i>Journal of Lipid Research</i> , 2005, 46, 1721-1731.	4.2	154
399	The Co-chaperone Carboxyl Terminus of Hsp70-interacting Protein (CHIP) Mediates $\beta$ -Synuclein Degradation Decisions between Proteasomal and Lysosomal Pathways. <i>Journal of Biological Chemistry</i> , 2005, 280, 23727-23734.	3.4	298
400	Detection of Myelination Using a Novel Histological Probe. <i>Journal of Histochemistry and Cytochemistry</i> , 2005, 53, 1511-1516.	2.5	51
401	Familial Alzheimer's Disease Presenilin 1 Mutations Cause Alterations in the Conformation of Presenilin and Interactions with Amyloid Precursor Protein. <i>Journal of Neuroscience</i> , 2005, 25, 3009-3017.	3.6	139
402	Low Density Lipoprotein Receptor-related Protein (LRP) Interacts with Presenilin 1 and Is a Competitive Substrate of the Amyloid Precursor Protein (APP) for $\beta$ -Secretase. <i>Journal of Biological Chemistry</i> , 2005, 280, 27303-27309.	3.4	57
403	Progression of Cerebral Amyloid Angiopathy in Transgenic Mouse Models of Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 588-594.	1.7	54
404	Transcriptional and conformational changes of the tau molecule in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2005, 1739, 150-157.	3.8	65
405	Transgenic models of Alzheimer's disease: Learning from animals. <i>NeuroRx</i> , 2005, 2, 423-437.	6.0	180
406	Anti- $\beta$ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. <i>Journal of Clinical Investigation</i> , 2005, 115, 428-433.	8.2	161
407	Cortical Synaptic Integration In Vivo Is Disrupted by Amyloid- $\beta$ Plaques. <i>Journal of Neuroscience</i> , 2004, 24, 4535-4540.	3.6	196
408	The membrane organization of leukotriene synthesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 6587-6592.	7.1	88
409	Serine and Threonine Phosphorylation of the Low Density Lipoprotein Receptor-related Protein by Protein Kinase C $\beta$ Regulates Endocytosis and Association with Adaptor Molecules. <i>Journal of Biological Chemistry</i> , 2004, 279, 40536-40544.	3.4	52
410	Neuronal Structure is Altered by Amyloid Plaques. <i>Reviews in the Neurosciences</i> , 2004, 15, 267-278.	2.9	96
411	Demonstration of BACE ( $\beta$ -secretase) phosphorylation and its interaction with GGA1 in cells by fluorescence-lifetime imaging microscopy. <i>Journal of Cell Science</i> , 2004, 117, 5437-5445.	2.0	103
412	Apolipoprotein E Receptors Mediate Neurite Outgrowth through Activation of p44/42 Mitogen-activated Protein Kinase in Primary Neurons. <i>Journal of Biological Chemistry</i> , 2004, 279, 34948-34956.	3.4	89
413	Apolipoprotein E modulates $\beta$ -secretase cleavage of the amyloid precursor protein. <i>Journal of Neurochemistry</i> , 2004, 90, 1132-1143.	3.9	85
414	Nonsteroidal anti-inflammatory drugs lower $\beta$ 242 and change presenilin 1 conformation. <i>Nature Medicine</i> , 2004, 10, 1065-1066.	30.7	206



#	ARTICLE	IF	CITATIONS
415	Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2004, 90, 724-733.	3.9	278
416	Activated Notch1 associates with a presenilin-1/ $\beta$ -secretase docking site. <i>Journal of Neurochemistry</i> , 2004, 87, 843-850.	3.9	18
417	Clinical, Pathological, and Biochemical Spectrum of Alzheimer Disease Associated With PS-1 Mutations. <i>American Journal of Geriatric Psychiatry</i> , 2004, 12, 146-156.	1.2	73
418	Geldanamycin induces Hsp70 and prevents $\beta$ -synuclein aggregation and toxicity in vitro. <i>Biochemical and Biophysical Research Communications</i> , 2004, 321, 665-669.	2.1	178
419	A single amino acid substitution differentiates Hsp70-dependent effects on $\beta$ -synuclein degradation and toxicity. <i>Biochemical and Biophysical Research Communications</i> , 2004, 325, 367-373.	2.1	43
420	Amyotrophic Lateral Sclerosis-Associated SOD1 Mutant Proteins Bind and Aggregate with Bcl-2 in Spinal Cord Mitochondria. <i>Neuron</i> , 2004, 43, 19-30.	8.1	452
421	$\beta$ -Secretase Activity Increases with Aging in Human, Monkey, and Mouse Brain. <i>American Journal of Pathology</i> , 2004, 164, 719-725.	3.8	267
422	Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimer's disease. <i>Neuroscience Letters</i> , 2004, 367, 228-231.	2.1	36
423	Hsp70 Reduces $\beta$ -Synuclein Aggregation and Toxicity. <i>Journal of Biological Chemistry</i> , 2004, 279, 25497-25502.	3.4	460
424	Neuritic alterations and neural system dysfunction in Alzheimer's disease and dementia with Lewy bodies. <i>Neurochemical Research</i> , 2003, 28, 1683-1691.	3.3	34
425	Live tissue intrinsic emission microscopy using multiphoton-excited native fluorescence and second harmonic generation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 7075-7080.	7.1	1,630
426	Designed Helical Peptides Inhibit an Intramembrane Protease. <i>Journal of the American Chemical Society</i> , 2003, 125, 11794-11795.	13.7	122
427	Motor dysfunction and gliosis with preserved dopaminergic markers in human $\beta$ -synuclein A30P transgenic mice. <i>Neurobiology of Aging</i> , 2003, 24, 245-258.	3.1	177
428	Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid $\beta$ -Protein Levels. <i>Archives of Neurology</i> , 2003, 60, 958.	4.5	250
429	Notch1 Competes with the Amyloid Precursor Protein for $\beta$ -Secretase and Down-regulates Presenilin-1 Gene Expression. <i>Journal of Biological Chemistry</i> , 2003, 278, 47370-47375.	3.4	45
430	Fluorescence resonance energy transfer determinations using multiphoton fluorescence lifetime imaging microscopy to characterize amyloid-beta plaques. <i>Journal of Biomedical Optics</i> , 2003, 8, 368.	2.6	150
431	The Intracellular Domain of the Low Density Lipoprotein Receptor-related Protein Modulates Transactivation Mediated by Amyloid Precursor Protein and Fe65. <i>Journal of Biological Chemistry</i> , 2003, 278, 41182-41188.	3.4	98
432	Uniform polarity microtubule assemblies imaged in native brain tissue by second-harmonic generation microscopy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 7081-7086.	7.1	253

#	ARTICLE	IF	CITATIONS
433	Î³-Secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila. FASEB Journal, 2003, 17, 79-81.	0.5	138
434	Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-Î ligand in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12462-12467.	7.1	253
435	Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. Journal of Cell Science, 2003, 116, 3339-3346.	2.0	247
436	Dysferlin Interacts with Annexins A1 and A2 and Mediates Sarcolemmal Wound-healing. Journal of Biological Chemistry, 2003, 278, 50466-50473.	3.4	336
437	Amyloid Precursor Protein Associates with a Nicastrin-Dependent Docking Site on the Presenilin 1-Î³-Secretase Complex in Cells Demonstrated by Fluorescence Lifetime Imaging. Journal of Neuroscience, 2003, 23, 4560-4566.	3.6	109
438	Amyloid-Î Antibody Treatment Leads to Rapid Normalization of Plaque-Induced Neuritic Alterations. Journal of Neuroscience, 2003, 23, 10879-10883.	3.6	152
439	<i>In Vivo</i> Imaging of Reactive Oxygen Species Specifically Associated with Thioflavine S-Positive Amyloid Plaques by Multiphoton Microscopy. Journal of Neuroscience, 2003, 23, 2212-2217.	3.6	150
440	Alzheimer's Disease: What Multiphoton Microscopy Teaches Us. Neuroscientist, 2002, 8, 386-390.	3.5	22
441	Î²-Macroglobulin Exposure Reduces Calcium Responses to N-Methyl-D-Aspartate via Low Density Lipoprotein Receptor-related Protein in Cultured Hippocampal Neurons. Journal of Biological Chemistry, 2002, 277, 14458-14466.	3.4	68
442	Colocalization and Fluorescence Resonance Energy Transfer between cdk5 and AT8 Suggests a Close Association in Pre-Neurofibrillary Tangles and Neurofibrillary Tangles. Journal of Neuropathology and Experimental Neurology, 2002, 61, 557-564.	1.7	66
443	Imaging Î² Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy-X04, a Systemically Administered Congo Red Derivative. Journal of Neuropathology and Experimental Neurology, 2002, 61, 797-805.	1.7	366
444	Caspase activation and neuroprotection in caspase-3-deficient mice after <i>in vivo</i> cerebral ischemia and <i>in vitro</i> oxygen glucose deprivation. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15188-15193.	7.1	285
445	Î²-Secretase Protein and Activity Are Increased in the Neocortex in Alzheimer Disease. Archives of Neurology, 2002, 59, 1381.	4.5	656
446	Dementia with Lewy bodies. , 2002, , 267-282.		0
447	The Î³ Secretase-generated Carboxyl-terminal Domain of the Amyloid Precursor Protein Induces Apoptosis via Tip60 in H4 Cells. Journal of Biological Chemistry, 2002, 277, 28530-28536.	3.4	121
448	Parkin Localizes to the Lewy Bodies of Parkinson Disease and Dementia with Lewy Bodies. American Journal of Pathology, 2002, 160, 1655-1667.	3.8	299
449	Disordered proteins in dementia. Annals of Medicine, 2002, 34, 259-271.	3.8	18
450	LRP and senile plaques in Alzheimer's disease: colocalization with apolipoprotein E and with activated astrocytes. Molecular Brain Research, 2002, 104, 38-46.	2.3	77

#	ARTICLE	IF	CITATIONS
451	An alternatively spliced form of rodent $\beta$ -synuclein forms intracellular inclusions in vitro: role of the carboxy-terminus in $\beta$ -synuclein aggregation. <i>Neuroscience Letters</i> , 2002, 323, 219-223.	2.1	31
452	Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid- $\beta$ In Vivo by Immunotherapy. <i>Journal of Neuroscience</i> , 2002, 22, 7873-7878.	3.6	314
453	Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2002, 22, 6331-6335.	3.6	417
454	GRO $\beta$ /KC, a chemokine receptor CXCR2 ligand, can be a potent trigger for neuronal ERK1/2 and PI-3 kinase pathways and for tau hyperphosphorylation—a role in Alzheimer's disease?. <i>Journal of Neuroimmunology</i> , 2002, 122, 55-64.	2.3	94
455	Patterns of protein nitration in dementia with Lewy bodies and striatonigral degeneration. <i>Acta Neuropathologica</i> , 2002, 103, 495-500.	7.7	29
456	Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2002, 103, 26-35.	7.7	849
457	A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 295-298.	2.2	343
458	Aspartate Mutations in Presenilin and $\beta$ -Secretase Inhibitors Both Impair Notch1 Proteolysis and Nuclear Translocation with Relative Preservation of Notch1 Signaling. <i>Journal of Neurochemistry</i> , 2002, 75, 583-593.	3.9	101
459	Low-density lipoprotein receptor-related protein levels and endocytic function are reduced by overexpression of the FE65 adaptor protein, FE65L1. <i>Journal of Neurochemistry</i> , 2002, 82, 755-762.	3.9	21
460	TorsinA and heat shock proteins act as molecular chaperones: suppression of $\beta$ -synuclein aggregation. <i>Journal of Neurochemistry</i> , 2002, 83, 846-854.	3.9	318
461	$\beta$ 2-Macroglobulin Enhances the Clearance of Endogenous Soluble $\beta$ -Amyloid Peptide via Low-Density Lipoprotein Receptor-Related Protein in Cortical Neuron. <i>Journal of Neurochemistry</i> , 2002, 73, 1393-1398.	3.9	122
462	Quantification of neurons in Alzheimer and control brains with ex vivo high resolution magic angle spinning proton magnetic resonance spectroscopy and stereology. <i>Magnetic Resonance Imaging</i> , 2002, 20, 527-533.	1.8	75
463	Imaging Amyloid- $\beta$ Deposits In Vivo. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002, 22, 1035-1041.	4.3	110
464	Glutamate Receptor Dysregulation in the Hippocampus of Transgenic Mice Carrying Mutated Human Amyloid Precursor Protein. <i>Neurobiology of Disease</i> , 2001, 8, 90-102.	4.4	32
465	A Close Association of TorsinA and $\beta$ -Synuclein in Lewy Bodies. <i>American Journal of Pathology</i> , 2001, 159, 339-344.	3.8	110
466	$\beta$ -Site APP Cleaving Enzyme mRNA Expression in APP Transgenic Mice. <i>American Journal of Pathology</i> , 2001, 158, 173-177.	3.8	62
467	Structural and Functional Disruption of Vascular Smooth Muscle Cells in a Transgenic Mouse Model of Amyloid Angiopathy. <i>American Journal of Pathology</i> , 2001, 158, 1065-1071.	3.8	130
468	Association of membrane-bound amyloid precursor protein APP with the apolipoprotein E receptor LRP. <i>Molecular Brain Research</i> , 2001, 87, 238-245.	2.3	53

#	ARTICLE	IF	CITATIONS
469	Effect of PS1 deficiency and an APP $\beta$ -secretase inhibitor on Notch1 signaling in primary mammalian neurons. <i>Molecular Brain Research</i> , 2001, 87, 166-174.	2.3	26
470	Demonstration by Fluorescence Resonance Energy Transfer of Two Sites of Interaction between the Low-Density Lipoprotein Receptor-Related Protein and the Amyloid Precursor Protein: Role of the Intracellular Adapter Protein Fe65. <i>Journal of Neuroscience</i> , 2001, 21, 8354-8361.	3.6	131
471	An Investigation of Clinical Correlates of Lewy Bodies in Autopsy-Proven Alzheimer Disease. <i>Archives of Neurology</i> , 2001, 58, 460-5.	4.5	54
472	Elevation of LDL Receptor-Related protein Levels via Ligand Interactions in Alzheimer Disease and In Vitro. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001, 60, 430-440.	1.7	36
473	Alzheimer Disease Therapeutics. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001, 60, 923-928.	1.7	42
474	Uptake of fibrillar $\beta$ -amyloid by microglia isolated from MSR-A (type I and type II) knockout mice. <i>NeuroReport</i> , 2001, 12, 1151-1154.	1.2	37
475	Cortical neurons expressing calcium binding proteins are spared in dementia with Lewy bodies. <i>Acta Neuropathologica</i> , 2001, 101, 36-42.	7.7	33
476	Alpha-synuclein has an altered conformation and shows a tight intermolecular interaction with ubiquitin in Lewy bodies. <i>Acta Neuropathologica</i> , 2001, 102, 329-334.	7.7	31
477	Interaction of $\beta$ -synuclein and synphilin-1: effect of Parkinson's disease-associated mutations. <i>Journal of Neurochemistry</i> , 2001, 77, 929-934.	3.9	65
478	Autoantibodies to amyloid- $\beta$ and Alzheimer's disease. <i>Annals of Neurology</i> , 2001, 49, 808-810.	5.3	132
479	No evidence for genetic association or linkage of the cathepsin D (CTSD) exon 2 polymorphism and Alzheimer disease. <i>Annals of Neurology</i> , 2001, 49, 114-116.	5.3	29
480	Imaging of amyloid- $\beta$ deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. <i>Nature Medicine</i> , 2001, 7, 369-372.	30.7	462
481	Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid $\beta$ -peptide. <i>Nature Cell Biology</i> , 2001, 3, 905-912.	10.3	444
482	Quantitation of apoE Domains in Alzheimer Disease Brain Suggests a Role for apoE in A $\beta$ Aggregation. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001, 60, 342-349.	1.7	100
483	Plaque-Induced Abnormalities in Neurite Geometry in Transgenic Models of Alzheimer Disease: Implications for Neural System Disruption. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001, 60, 753-758.	1.7	88
484	Notch1 and Amyloid Precursor Protein Are Competitive Substrates for Presenilin1-dependent $\beta$ -Secretase Cleavage. <i>Journal of Biological Chemistry</i> , 2001, 276, 30018-30023.	3.4	71
485	Microtubule-Affinity Regulating Kinase (MARK) Is Tightly Associated with Neurofibrillary Tangles in Alzheimer Brain: A Fluorescence Resonance Energy Transfer Study. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000, 59, 966-971.	1.7	82
486	Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. <i>Annals of Neurology</i> , 2000, 47, 430-439.	5.3	607

#	ARTICLE	IF	CITATIONS
487	Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. <i>Annals of Neurology</i> , 2000, 47, 739-747.	5.3	293
488	Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer's disease. <i>Journal of Neuroimmunology</i> , 2000, 108, 227-235.	2.3	243
489	Senile dementia associated with amyloid $\beta^2$ protein angiopathy and tau perivascular pathology but not neuritic plaques in patients homozygous for the APOE- $\mu$ 4 allele. <i>Acta Neuropathologica</i> , 2000, 100, 1-12.	7.7	74
490	Fas Receptor and Neuronal Cell Death after Spinal Cord Ischemia. <i>Journal of Neuroscience</i> , 2000, 20, 6879-6887.	3.6	125
491	Membrane Association and Protein Conformation of $\beta$ -Synuclein in Intact Neurons. <i>Journal of Biological Chemistry</i> , 2000, 275, 8812-8816.	3.4	219
492	Role of the Low-density Lipoprotein Receptor-Related Protein in $\beta^2$ -Amyloid Metabolism and Alzheimer Disease. <i>Archives of Neurology</i> , 2000, 57, 646.	4.5	105
493	Modulation of $\beta^2$ -Amyloid Precursor Protein Processing by the Low Density Lipoprotein Receptor-related Protein (LRP). <i>Journal of Biological Chemistry</i> , 2000, 275, 7410-7415.	3.4	233
494	Endocytic Pathway Abnormalities Precede Amyloid $\beta^2$ Deposition in Sporadic Alzheimer's Disease and Down Syndrome. <i>American Journal of Pathology</i> , 2000, 157, 277-286.	3.8	737
495	Age-Related Amyloid $\beta^2$ Deposition in Transgenic Mice Overexpressing Both Alzheimer Mutant Presenilin 1 and Amyloid $\beta^2$ Precursor Protein Swedish Mutant Is Not Associated with Global Neuronal Loss. <i>American Journal of Pathology</i> , 2000, 157, 331-339.	3.8	222
496	Evidence against association of the FE65 gene (APBB1) intron 13 polymorphism in Alzheimer's patients. <i>Neuroscience Letters</i> , 2000, 296, 17-20.	2.1	18
497	Rapid Notch1 Nuclear Translocation after Ligand Binding Depends on Presenilin-associated $\beta$ -Secretase Activity. <i>Annals of the New York Academy of Sciences</i> , 2000, 920, 223-226.	3.8	29
498	Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. <i>Annals of Neurology</i> , 2000, 47, 430-439.	5.3	14
499	Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. <i>Journal of NeuroVirology</i> , 1999, 5, 32-41.	2.1	258
500	Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. <i>Nature Neuroscience</i> , 1999, 2, 271-276.	14.8	855
501	Lack of association of presenilin-1 intron-8 polymorphism with neuropathological features of Alzheimer's disease. <i>Brain Research</i> , 1999, 816, 295-298.	2.2	10
502	Lack of allelic imbalance in APOE $\mu$ 3/4 brain mRNA expression in Alzheimer's disease. <i>Neuroscience Letters</i> , 1999, 272, 83-86.	2.1	20
503	Lack of independent associations of apolipoprotein E promoter and intron 1 polymorphisms with Alzheimer's disease. <i>Neuroscience Letters</i> , 1999, 272, 155-158.	2.1	38
504	$\beta$ -Synuclein Immunoreactivity Is Present in Axonal Swellings in Neuroaxonal Dystrophy and Acute Traumatic Brain Injury. <i>Journal of Neuropathology and Experimental Neurology</i> , 1999, 58, 1263-1268.	1.7	118

#	ARTICLE	IF	CITATIONS
505	Demonstration by Fluorescence Resonance Energy Transfer of a Close Association Between Activated MAP Kinase and Neurofibrillary Tangles: Implications for MAP Kinase Activation in Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 1999, 58, 1090-1098.	1.7	61
506	Application of the National Institute on Aging (NIA)-Reagan Institute Criteria for the Neuropathological Diagnosis of Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 1999, 58, 1147-1155.	1.7	240
507	Risperidone Treatment of Behavioral Disturbances in Outpatients With Dementia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1999, 11, 336-342.	1.8	29
508	Alpha-2 macroglobulin is genetically associated with Alzheimer disease. <i>Nature Genetics</i> , 1998, 19, 357-360.	21.4	680
509	Attenuation of Delayed Neuronal Death after Mild Focal Ischemia in Mice by Inhibition of the Caspase Family. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1998, 18, 238-247.	4.3	532
510	Statistical physics and Alzheimer's disease. <i>Physica A: Statistical Mechanics and Its Applications</i> , 1998, 249, 460-471.	2.6	13
511	Immunohistochemical and in situ analysis of amyloid precursor-like protein-1 and amyloid precursor-like protein-2 expression in Alzheimer disease and aged control brains. <i>Brain Research</i> , 1998, 804, 45-51.	2.2	39
512	Immunohistochemical Study of the $\beta$ -Chemokine Receptors CCR3 and CCR5 and Their Ligands in Normal and Alzheimer's Disease Brains. <i>American Journal of Pathology</i> , 1998, 153, 31-37.	3.8	274
513	Lack of specific association of presenilin 1 (PS-1) protein with plaques and tangles in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 1998, 158, 15-23.	0.6	6
514	Utility of the Apolipoprotein E Genotype in the Diagnosis of Alzheimer's Disease. <i>New England Journal of Medicine</i> , 1998, 338, 506-511.	27.0	530
515	Apolipoprotein E Genotype and Deposits of $A\beta^{240}$ and $A\beta^{242}$ in Alzheimer Disease. <i>Archives of Neurology</i> , 1998, 55, 1001.	4.5	60
516	$A\beta^{2}$ Associated Neuropil Changes. <i>Journal of Neuropathology and Experimental Neurology</i> , 1998, 57, 1122-1130.	1.7	71
517	Stereology: A Practical Primer for Neuropathology. <i>Journal of Neuropathology and Experimental Neurology</i> , 1998, 57, 305-310.	1.7	77
518	Nigral and Cortical Lewy Bodies and Dystrophic Nigral Neurites in Parkinson's Disease and Cortical Lewy Body Disease Contain $\beta$ -synuclein Immunoreactivity. <i>Journal of Neuropathology and Experimental Neurology</i> , 1998, 57, 334-337.	1.7	355
519	Progression of Cerebral Amyloid Angiopathy: Accumulation of Amyloid- $\beta$ 40 in Affected Vessels. <i>Journal of Neuropathology and Experimental Neurology</i> , 1998, 57, 353-359.	1.7	164
520	Dementia with Lewy Bodies. <i>Journal of the American Geriatrics Society</i> , 1998, 46, 1449-1458.	2.6	37
521	Unraveling the Mystery of Cognitive Changes in Old Age: Correlation of Neuropsychological Evaluation With Neuropathological Findings in the Extreme Old. <i>International Psychogeriatrics</i> , 1998, 10, 25-41.	1.0	40
522	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Neurotoxicity Is Attenuated in Mice Overexpressing Bcl-2. <i>Journal of Neuroscience</i> , 1998, 18, 8145-8152.	3.6	193



#	ARTICLE	IF	CITATIONS
523	Cerebrovascular Pathology Contributes to the Heterogeneity of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 1998, 1, 119-134.	2.6	72
524	Effects of Age and Ethnicity on the Link Between <i>APOE</i> $\epsilon$ 4 and Alzheimer Disease—Reply. <i>JAMA - Journal of the American Medical Association</i> , 1998, 279, 581.	7.4	4
525	Role of the $\beta$ -Chemokine Receptors CCR3 and CCR5 in Human Immunodeficiency Virus Type 1 Infection of Monocytes and Microglia. <i>Journal of Virology</i> , 1998, 72, 3351-3361.	3.4	146
526	H. M.'s Medial Temporal Lobe Lesion: Findings from Magnetic Resonance Imaging. <i>Journal of Neuroscience</i> , 1997, 17, 3964-3979.	3.6	407
527	Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 1997, 56, 1095-1097.	1.7	872
528	Developmental Regulation of Presenilin mRNA Expression Parallels Notch Expression. <i>Journal of Neuropathology and Experimental Neurology</i> , 1997, 56, 40-44.	1.7	65
529	APP <sup>SW</sup> Transgenic Mice Develop Age-related $A\beta$ Deposits and Neuropil Abnormalities, but no Neuronal Loss in CA1. <i>Journal of Neuropathology and Experimental Neurology</i> , 1997, 56, 965-973.	1.7	597
530	MPP+Induced Substantia Nigra Degeneration Is Attenuated in nNOS Knockout Mice. <i>Neurobiology of Disease</i> , 1997, 4, 114-121.	4.4	63
531	$A\beta$ Deposition Is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse. <i>Journal of Neuroscience</i> , 1997, 17, 7053-7059.	3.6	490
532	Mechanisms of Reduced Striatal NMDA Excitotoxicity in Type I Nitric Oxide Synthase Knock-Out Mice. <i>Journal of Neuroscience</i> , 1997, 17, 6908-6917.	3.6	187
533	Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. <i>Annals of Neurology</i> , 1997, 41, 17-24.	5.3	1,243
534	Cerebral amyloid angiopathy and apolipoprotein E: Bad news for the good allele?. <i>Annals of Neurology</i> , 1997, 41, 701-702.	5.3	26
535	Glycogen synthase kinase $3\beta$ and $3\delta$ do not colocalize with neurofibrillary tangles. <i>Neurobiology of Aging</i> , 1996, 17, 343-348.	3.1	18
536	Neuropathological markers of impaired cognition in the entorhinal cortex. <i>Neurobiology of Aging</i> , 1996, 17, 940-941.	3.1	5
537	Characterization of the Precursor Protein of the Non- $A\beta$ Component of Senile Plaques (NACP) in the Human Central Nervous System. <i>Journal of Neuropathology and Experimental Neurology</i> , 1996, 55, 889-895.	1.7	185
538	Expression of the Very Low-Density Lipoprotein Receptor (VLDL-r), an Apolipoprotein-E Receptor, in the Central Nervous System and in Alzheimer's Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 1996, 55, 491.	1.7	97
539	GERIATRIC BIOSCIENCE: Apolipoprotein E Genotype: Utility in Clinical Practice in Alzheimer's Disease. <i>Journal of the American Geriatrics Society</i> , 1996, 44, 1469-1471.	2.6	9
540	Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer's Disease. <i>Journal of Neuroscience</i> , 1996, 16, 4491-4500.	3.6	1,570

#	ARTICLE	IF	CITATIONS
541	Clinical and pathological correlates of apolipoprotein E $\epsilon$ 4 in Alzheimer's disease. <i>Annals of Neurology</i> , 1996, 39, 62-70.	5.3	380
542	Lack of association of trinucleotide repeat polymorphisms in the very-low-density lipoprotein receptor gene with Alzheimer's disease. <i>Annals of Neurology</i> , 1996, 39, 800-803.	5.3	30
543	Alzheimer's disease or Alzheimer's diseases? clues from molecular epidemiology. <i>Annals of Neurology</i> , 1996, 40, 135-136.	5.3	18
544	Alzheimer-associated presenilins 1 and 2 : Neuronal expression in brain and localization to intracellular membranes in mammalian cells. <i>Nature Medicine</i> , 1996, 2, 224-229.	30.7	573
545	Amyloid $\beta$ -Peptide Is Transported on Lipoproteins and Albumin in Human Plasma. <i>Journal of Biological Chemistry</i> , 1996, 271, 32916-32922.	3.4	286
546	Brain Expression of Apolipoproteins E, J, and $\epsilon$ in Alzheimer's Disease. <i>Journal of Neurochemistry</i> , 1996, 66, 2429-2435.	3.9	154
547	Apolipoprotein E $\epsilon$ 4 Is Associated With the Presence and Earlier Onset of Hemorrhage in Cerebral Amyloid Angiopathy. <i>Stroke</i> , 1996, 27, 1333-1337.	2.0	212
548	Functional Alterations in Alzheimer's Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 1995, 54, 38-41.	1.7	90
549	Regional Variation in the Distribution of Apolipoprotein E and $\beta$ in Alzheimer's Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 1995, 54, 833-841.	1.7	56
550	Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 1995, 54, 132.	1.7	0
551	Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein e receptor, the $\beta$ 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein. <i>Annals of Neurology</i> , 1995, 37, 211-217.	5.3	304
552	Cerebrospinal fluid levels of amyloid $\beta$ protein in alzheimer's disease: Inverse correlation with severity of dementia and effect of apolipoprotein e genotype. <i>Annals of Neurology</i> , 1995, 37, 512-518.	5.3	117
553	Apolipoprotein E $\epsilon$ 4 and cerebral hemorrhage associated with amyloid angiopathy. <i>Annals of Neurology</i> , 1995, 38, 254-259.	5.3	488
554	Apolipoprotein E $\epsilon$ 4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 1995, 38, 460-463.	5.3	80
555	Neuropathological Changes in Down's Syndrome Hippocampal Formation. <i>Archives of Neurology</i> , 1995, 52, 373.	4.5	139
556	Molecular Epidemiology of Alzheimer's Disease. <i>New England Journal of Medicine</i> , 1995, 333, 1283-1284.	27.0	23
557	CA3 neuronal degeneration follows chronic entorhinal cortex lesions. <i>Neuroscience Letters</i> , 1995, 197, 1-4.	2.1	27
558	LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted $\beta$ -amyloid precursor protein and mediates its degradation. <i>Cell</i> , 1995, 82, 331-340.	28.9	499



#	ARTICLE	IF	CITATIONS
559	Functional alterations in neural circuits in Alzheimer's disease. <i>Neurobiology of Aging</i> , 1995, 16, 305-309.	3.1	20
560	Localization of non-N-methyl-D-aspartate glutamate receptors in normal and Alzheimer hippocampal formation. <i>Annals of Neurology</i> , 1994, 35, 31-37.	5.3	32
561	?2-Macroglobulin Receptor/Low Density Lipoprotein Receptor?Related Protein.. <i>Annals of the New York Academy of Sciences</i> , 1994, 737, 88-95.	3.8	12
562	Extracellular signal-regulated kinase (MAP kinase) immunoreactivity in the rhesus monkey brain. <i>Neuroscience Letters</i> , 1994, 166, 113-116.	2.1	14
563	Frequency of the apolipoprotein E $\epsilon$ 2 allele is diminished in sporadic Alzheimer disease. <i>Neuroscience Letters</i> , 1994, 175, 46-48.	2.1	119
564	Chapter 30 Functional integrity of neural systems related to memory in Alzheimer's disease. <i>Progress in Brain Research</i> , 1994, 100, 245-254.	1.4	5
565	Apolipoprotein E, $A\beta$ , and Alzheimer Disease. An Editorial Comment. <i>Journal of Neuropathology and Experimental Neurology</i> , 1994, 53, 427-428.	1.7	15
566	Functional Alterations in Alzheimer's Disease: Selective Loss of Mitochondrial-encoded Cytochrome Oxidase mRNA in the Hippocampal Formation. <i>Journal of Neuropathology and Experimental Neurology</i> , 1994, 53, 508-512.	1.7	106
567	Development of the Superior Temporal Neocortex Is Anomalous in Trisomy 21. <i>Journal of Neuropathology and Experimental Neurology</i> , 1994, 53, 513-520.	1.7	182
568	Isolation and characterization of APLP2 encoding a homologue of the Alzheimer's associated amyloid $\beta$ protein precursor. <i>Nature Genetics</i> , 1993, 5, 95-100.	21.4	370
569	Age-Dependent Striatal Excitotoxic Lesions Produced by the Endogenous Mitochondrial Inhibitor Malonate. <i>Journal of Neurochemistry</i> , 1993, 61, 1147-1150.	3.9	289
570	Age-Dependent Vulnerability of the Striatum to the Mitochondrial Toxin $\beta$ -Nitropropionic Acid. <i>Journal of Neurochemistry</i> , 1993, 60, 356-359.	3.9	365
571	Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?. <i>Trends in Neurosciences</i> , 1993, 16, 125-131.	8.6	563
572	Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions. <i>Neuron</i> , 1993, 11, 575-580.	8.1	1,057
573	Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: A stereological estimate of neuronal loss. <i>Neurobiology of Aging</i> , 1993, 14, 295-301.	3.1	98
574	Neuroanatomical connections and specific regional vulnerability in Alzheimer's disease. <i>Neurobiology of Aging</i> , 1993, 14, 45-47.	3.1	27
575	Cellular specificity and regional distribution of amyloid $\beta$ protein precursor alternative transcripts are unaltered in Alzheimer hippocampal formation. <i>Molecular Brain Research</i> , 1993, 18, 246-252.	2.3	38
576	The pattern of NADPH-diaphorase staining, a marker of nitric oxide synthase activity, is altered in the perforant pathway terminal zone in Alzheimer's disease. <i>Neuroscience Letters</i> , 1993, 152, 165-168.	2.1	32

#	ARTICLE	IF	CITATIONS
577	The Lack of Accumulation of Senile Plaques or Amyloid Burden in Alzheimer's Disease Suggests a Dynamic Balance Between Amyloid Deposition and Resolution. <i>Journal of Neuropathology and Experimental Neurology</i> , 1993, 52, 594-600.	1.7	241
578	Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. <i>Neurology</i> , 1992, 42, 631-631.	1.1	2,379
579	Alteration in the pattern of nerve terminal protein immunoreactivity in the perforant pathway in Alzheimer's disease and in rats after entorhinal lesions. <i>Neurobiology of Aging</i> , 1992, 13, 283-291.	3.1	62
580	1-Methyl-4-Phenylpyridinium Produces Excitotoxic Lesions in Rat Striatum as a Result of Impairment of Oxidative Metabolism. <i>Journal of Neurochemistry</i> , 1992, 58, 1975-1978.	3.9	162
581	Relative sparing of nitric oxide synthase-containing neurons in the hippocampal formation in Alzheimer's disease. <i>Annals of Neurology</i> , 1992, 32, 818-820.	5.3	177
582	Effects of aging on quinolinic acid lesions in rat striatum. <i>Brain Research</i> , 1991, 562, 276-280.	2.2	20
583	Studies of Amyloid $\beta$ -Protein Precursor Expression in Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 1991, 640, 149-154.	3.8	11
584	Pathologic Changes in the Olfactory System in Aging and Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 1991, 640, 14-19.	3.8	64
585	Alzheimer's mutation. <i>Nature</i> , 1991, 350, 564-564.	27.8	66
586	Aminooxyacetic Acid Results in Excitotoxin Lesions by a Novel Indirect Mechanism. <i>Journal of Neurochemistry</i> , 1991, 57, 1068-1073.	3.9	113
587	Entorhinal cortex pathology in Alzheimer's disease. <i>Hippocampus</i> , 1991, 1, 1-8.	1.9	418
588	Chapter 32 Hippocampal formation: anatomy and the patterns of pathology in Alzheimer's disease. <i>Progress in Brain Research</i> , 1990, 83, 445-457.	1.4	171
589	Alz-50 immunoreactivity in the thalamic reticular nucleus in Alzheimer's disease. <i>Brain Research</i> , 1990, 515, 227-234.	2.2	29
590	Hemianesthesia and Aphasia. <i>Archives of Neurology</i> , 1989, 46, 816.	4.5	24
591	A direct demonstration of the perforant pathway terminal zone in Alzheimer's disease using the monoclonal antibody Alz-50. <i>Brain Research</i> , 1988, 450, 392-397.	2.2	79
592	Warfarin-related purple toes syndrome and cholesterol microembolization. <i>American Journal of Medicine</i> , 1987, 82, 1233-1237.	1.5	156
593	Neuron numbers in Alzheimer's disease: Cell-specific pathology. <i>Neurobiology of Aging</i> , 1987, 8, 555-556.	3.1	8
594	Alzheimer's disease: Glutamate depletion in the hippocampal perforant pathway zone. <i>Annals of Neurology</i> , 1987, 22, 37-40.	5.3	212

#	ARTICLE	IF	CITATIONS
595	Glycine Uptake by Cultured Human Y79 Retinoblastoma Cells: Effect of Changes in Phospholipid Fatty Acid Unsaturation. <i>Journal of Neurochemistry</i> , 1983, 40, 70-78.	3.9	33
596	Choline Uptake in Cultured Human Y79 Retinoblastoma Cells: Effect of Polyunsaturated Fatty Acid Compositional Modifications. <i>Journal of Neurochemistry</i> , 1982, 38, 650-656.	3.9	48
597	Fatty acid and lipid composition of the monkey retina in diet-induced hypercholesterolemia. <i>Atherosclerosis</i> , 1981, 40, 321-328.	0.8	15
598	Accumulation of N-3 Polyunsaturated Fatty Acids by Cultured Human Y79 Retinoblastoma Cells. <i>Journal of Neurochemistry</i> , 1981, 37, 60-69.	3.9	52